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ABSTRACT
Marketing factors such as pricing and branding are known to affect people's judgments
and expectations regarding a product. When the product in question is a medical
treatment, this effect may modify the placebo response. As the placebo response
modifies the overall effect of the treatment in an additive manner, this implies that
marketing factors may have a direct effect on medical outcomes, particularly in disorders
that have large placebo effects. This thesis explores this idea. First a laboratory study is
presented that used electric shocks and a placebo pill to demonstrate that a price discount
may reduce the efficacy of a placebo analgesic. A second laboratory study, using the
cold pressor test and a medication with low non-placebo efficacy, failed to demonstrate
superiority of a brand-name over generic medication in terms of cold tolerance or pain
ratings, but the brand-name did lead to quicker habituation to the cold pain. In addition,
quantitative and qualitative research exploring attitudes held towards generic medications
shows conflicted beliefs and a lack of complete trust in generic medications in both
general and geriatric populations. "Non-commercial" forms of marketing, including the
labeling of, and description of, a disorder, are also touched upon. The implications of
this research for marketing are discussed, as well as necessary steps for the research
development of this field.
Thesis Supervisor: Dan Ariely
Title: Professor of Media Arts and Sciences, Professor of Marketing

The Role of Branding and Pricing on Health Outcomes via the Placebo Response
by
Rebecca L. Waber
The Following Served As Readers
1 /?
Edward Boyden, PhD:






Expectation and narrative 10
The placebo effect 12





The placebo effect in clinical trials 16
Pain 17
Price-quality assumption 18
Laboratory Experiment 1 21
Veladone Experiment Methods 21
Subjects and recruitment 21
Procedure 21




Price interacts with subject's other pain experiences 26
Veladone Experiment Discussion 27
Laboratory Experiment 2 29
Significance of Brand Name 29
Brand as cultural information 29
Surveys on attitudes towards generic medications 31
Qualitative Interviews 32
Patient Education 33
Implication of distrust of generics 34
Cold Pressor Experiment Methods 34
Cold Pressor Experiment Results 38
Description of the subjects 38
Subjects' Attitudes towards generics 38
Time course of pain ratings differs by condition 38
Cold pressor time by be increased by brand only in extreme
responders 40
Non-brand modifiers of dependent measures 42
The cold pressor as an experimental task 43
Cold Pressor Experiment Discussion 46
Discussion of Results 46
Limitations of the study 46
Cold Pressor Follow-up study 49
Non-Commercial Forms of "Marketing" 50
Biased judgments of self-ratings 50
Effect of 'biological' labeling 52
Overall Discussion 54
Implications for marketing 54
Future Research 56
Table of Figures, tables, and Graphics
Figure 1: The timeline of the Veladone experiment 23
Table 2: Veladone mixed-model regression 24
Figure 2: Veladone Price difference across intensities 25
Figure 3: Country of origin interaction with Ethnicity 26
Figure 4: Price interaction with Recent Pain 27
Graphic 1: Valium ad 30
Graphic 2: Brand and Generic Medication photo 36
Graphic 3: Set-up for cold pressor test 37
Table 2: Attitudes towards generics in cold pressor subjects 38
Figure 5: Pain ratings across time all subjects 39
Figure 6: Pain ratings by Condition 49
Figure 7: Cold pressor time, first round 41
Figure 8: Cold pressor time, second round 42
Figure 9: Ratings below "600" first round 44
Figure 10: Ratings below "600" second round 45
Figure 11: Difference in ratings below "600" 46
Graphic 4: Advertisements for ADHD studies 51
Graphic 5: Alcoholism advertisement 53
Background
Introduction
When 'marketing' and 'healthcare' are spoken of together, the two fields are typically
thought of as, if not directly at odds with each other, then at least partners in an uneasy
relationship. The discussion is typically concerned with the effect of direct-to-consumer
advertising on prescribing habits or the biasing effect of pharmaceutical company gifts.
These are, of course, very important research topics.
However, there exists another potential link between marketing and healthcare which has
not been well examined. Marketing factors, such as pricing and branding, are well
known to influence perception and expectation. Since expectation and beliefs are the
main drivers of the placebo response, it is possible that marketing factors may modify the
placebo response. Because the placebo response is an important component of many
medical outcomes, it is logical to postulate that a manipulation of price or brand could
have a direct effect on medical outcomes by modifying the placebo response. This issue
has not before been raised by medical or psychological research, but the potential public
health effect could potentially be quite significant and therefore demands research
attention.
The goal of this thesis is to initiate research on this topic. Two laboratory experiments
and several questionnaire and interview based studies are presented in order to take the
first steps in considering the direct role of commercial information on health outcomes.
Expectation and narrative
The 'gold standard' blind clinical trial is designed to create an impartial testing system
which allows only specifically efficacious treatments to make it into the medical
marketplace, and this system has been effective in creating many vital medical advances.
Another implication of our reliance of this system, however, is the denial of the role of
myth, ritual, and non-specific healing in modem medicine. Accordingly, the role of the
placebo effect in medical treatments has often been looked upon unfavorably (de Craen,
Kaptchuk, Tijssen, & Kleijnen, 1999).
The placebo effect can have negative connotations, conjuring up images of 19th-century
snake oil sellers or primitive religious healing rituals. However, a great number of
products thrive today which are not FDA tested or approved (herbal supplements, diet
pills, and so on), and the concept of 'evidence-based' medicine remains a hot topic of
discussion rather than being naturally embedded in the consciousness of practitioners. In
fact, the question of to what extent healing can relate to myth and ritual in modem
medicine is a fascinating one (Kaptchuk, 2002). A 1944 article by Canon was perhaps
the first well-known paper to suggest such a link, discussing the anthropological concept
of 'voodoo death' (or the ability of a 'curse' to cause death). He posited that the
phenomenon might be authentic, having a corollary with instances in modem medicine
such as when someone dies, for instance from shock, without any visible cause for death
(Cannon, 1957). He speculated that acute fear might cause such a result (Sternberg,
2002).
Another fascinating article on the potential relationship between ritual and modern
medicine is a case report by Dr. Clifton Meador. The first case involved voodoo death.
A patient seemed to be dying, barely conscious, apparently following a curse by a voodoo
priest. The physician performed a ritual within the context of the curse, which was
followed by the recovery of the patient. Instead of confining such a situation to a certain
foreign culture, Dr. Meador went on to describe what he considered a possible
comparable situation, the case of a patient in a mainstream medical setting who was
diagnosed with esophageal cancer. The patient and all the doctors firmly believed he
would die soon, but autopsy was unable to find a cause of death, the cancer diagnosis
apparently being a false positive (Meador, 1992).
Finally, Dr. Herbert Spiegel reported an anecdote in a modern Catholic hospital, in which
a priest mistakenly gave last rites to the wrong patient, who died quickly thereafter
(Spiegel, 1997). Other such anecdotes exist (Weisman & Hackett, 1961), but articles on
this topic appeared for the most part in the 1950s and 60s, under the influence of
psychoanalysis, and have not been much seriously considered since. Naturally, as
anecdotes these stories must be approached with caution, and yet they are thought-
provoking. The assumption that our medical system has cut its ties to the human
imagination is appealing but perhaps overzealous.
It is interesting to consider what form modem superstitions might take. Arguably, some
of these superstitions could be cognitive heuristics relating to issues like price-quality
assumptions, belief in brand names, or the effect of disease labels.
On the issue of price-quality assumptions, there are corollaries from other traditions.
Traditional healing substances are often those that are difficult to obtain and expensive,
such as rhino horn or tiger bone (Bensky, 1986). And in Reiki, a spiritual healing
practice involving the transfer of energy through the hands, a traditional caveat is that
money must be charged in order for clients to value the treatment enough for it to work.
One Reiki practitioner asked about this idea agreed that in everyday practice this
condition seemed to be accurate, and that that charging more implied that the healer's
services were worth more, which led to obtaining the same healing result in less time
(Director, Reiki Center of Greater Washington, personal communication, April 16 2008).
To date however, there has not been much research on the role of prices or marketing on
the placebo effect and medical treatments specifically, although the idea that direct-to-
consumer advertising might produce a useful placebo effect was actually posited in one
2006 paper (Almasi, Stafford, Kravitz, & Mansfield, 2006). In addition, one recent
anthropology thesis analyzed in depth the relationship that patients can have with their
medications, particularly as a result of direct-to-consumer advertising and branding
(Greenslit, 2005). There is also some evidence that the enhanced effectiveness of
antidepressant drugs over the past few decades could be a response to increased
marketing and societal faith in the drugs (Walsh, 1983).
In essence, the role of marketing, myth, and ritual is one of epistemology. Is the value of
a medical product established solely through clinical trial results, or do people in the real
world assign additional value to it as a function of heuristics of prices, brands, and other
informational signals?
The Placebo Effect
Introduction to the Placebo Effect
The placebo effect may be one of the most powerful underappreciated forces in medicine.
To begin with, when discussing these effects, it's important to keep terminology clear. A
placebo itself, such as the classic 'sugar pill,' may help engender placebo effects.
However, it is not the pill itself causing the reaction, but rather the significance and
meaning involved in taking the pill. This is why Dr. Daniel Moerman, a well-known
researcher on the placebo effect, argues that a better term for the phenomenon would be
"meaning effects (D. E. Moerman & Jonas, 2002)." Studying the placebo effect
essentially means studying the psychosocial context surrounding a medical treatment
(Colloca & Benedetti, 2005).
Placebo effects have long played a key role in medicine. For thousands of years many
medical treatments were without specific objective effect and thus relied exclusively on
placebo responses. While the mechanism underlying placebo responses differs with the
ailment, placebos still play an important role in medicine. Strong placebo effects have
been demonstrated in many conditions, including coronary artery disease (Granger et al.,
2005), depression (Leuchter et al., 2004), pain (Price et al., 1999), Parkinson's disease
(Pollo et al., 2002), irritable bowel syndrome (Patel et al., 2005), and many others (Koshi
& Short, 2007). Imaging technologies, behavioral studies, and clinical data have shown
that responsiveness to placebo reflects physiologic changes in the body, such as
endorphin activation in the case of analgesia (Zubieta et al., 2005), and can thus be
thought of as the body recruiting its healing abilities in response to beliefs and
expectations (Brody, 2000).
The implications of the placebo effect are not limited to treatments with placebos. (In
fact, knowing that one is taking a placebo would naturally decrease the placebo response
produced by it), and strong effects can also be found with medications, medical devices
(Long, Uematsu, & Kouba, 1989), and physical manipulations (Kaptchuk, Goldman,
Stone, & Stason, 2000). Although the archetypical placebo is the sugar pill, there are
many other types of placebos. Irrespective of the type of treatment, the placebo effect
occurs when the patient believes that an experience will help their condition. Back in the
1950s, a treatment for angina called mammary artery ligation was popular; doctors and
patients reported considerable success with the procedure. However, after a double-blind
clinical trial utilizing sham surgery for one group of patients showed no greater efficacy
for the procedure over the placebo surgery, the procedure was abandoned. To most
people, this experiment simply demonstrated that the well-liked ligation procedure was a
failure, but it is also a striking example of the power of placebo. All the patients believed
they would be helped by the procedure, and they were, in terms of needing less
nitroglycerin and increasing their exercise tolerance (Cobb, 1959 as cited in (D. Moerman,
2002). In addition to demonstrating the ineffectiveness of mammary artery ligation, this
story showcases the usefulness of placebo.
Context Effects
The placebo effect is not constant. Actually, there can be remarkable variability in a
placebo response even when considering the same treatment for the same disease (D. E.
Moerman, 2000). Placebo responses can be quite strong, but they are also extremely
sensitive to contextual factors in the environment, and can thus vary considerably across
situations. Factors that have been shown to modulate the placebo response physician
attitude, confidence, belief in the drug (Thomas, 1987) (Gracely, Dubner, Deeter, &
Wolskee, 1985), and even the color of the pill (such as red pills being better as stimulants
than depressants, to go along with usual meanings of those colors) (Blackwell,
Bloomfield, & Buncher, 1972) (Lucchelli, Cattaneo, & Zattoni, 1978).
Expectations and the meaning of contextual effects drive the placebo response (Koyama,
McHaffie, Laurienti, & Coghill, 2005) (Colloca & Benedetti, 2005). For instance, a
person might have stronger expectations for a medication that is administered via an
injection rather than a pill, given in a hospital rather than at the local doctor's office, or
when the physician's attitude toward the medicine is enthusiastic rather than ambivalent
(Benedetti, 2002)'. These and others factors influence what the patient anticipates and
accordingly influence the overall efficacy of the treatment.
Additional evidence that placebo effects are a result of expectation are that Alzheimers'
patients, as well as people who do not know that they are being giving a medication, do
not experience these effects (Benedetti et al., 2006), (Kirsch, 2003), and that
surreptitiously reducing the pain of the treatment while giving a placebo will
consequently imbue that placebo with pain-reducing abilities (Price et al., 1999).
Placebo effects have been viewed and used in very different ways across history and
cultures, from acceptance to skepticism and from viewing it as a positive phenomenon to
a negative one (de Craen et al., 1999). The negative reputation is often related to the idea
that placebo effects interfere with finding real drug effects, since clinical trials are based
upon comparing placebo and active groups. The negative view of the placebo effect had
been the dominant view of the placebo effect for the past several decades. However,
recently, some researchers and clinicians have become interested in harnessing the
placebo effect for patient well-being.
Nocebo
Placebo effects are most commonly thought of in connection to healing, but placebo
effects are not necessarily in a positive direction. Belief and expectation can just as
readily be harmful to health. This negative action is sometimes called the nocebo effect,
but it is simply another incarnation of the placebo effect. The same treatment, with a
different expectation, can produce wildly different effects. In one classic experiment, a
physician gave subjects either ipecac (which causes vomiting) or atropine (which soothes
the stomach). He used a tool inserted into the stomach so that he could actually visualize
the effects of the medicines. Then he gave his subjects an inactive substance and told
them either that it was ipecac or that it was atropine, and actually watched the stomach
wave patterns behave in accordance with their expectations. In one patient, he even gave
ipecac saying it was atropine, and vice versa, and observed the stomach wave patterns
match expectation instead of chemistry (Brody, 2000).
Adverse drug effects are an extremely important issue, as they can spell the end to
otherwise successful pharmaceuticals. However, it is difficult to disentangle placebo
from specific side effects, particularly because even no-treatment (people given no
treatment of any kind, including placebo treatment) control subjects will often report
having symptoms when asked about them. Therefore, no-treatment control conditions
are not often performed, making it difficult to know how far above baseline reported
negative side effects really are (Khosla, Bajaj, Sharma, & Mishra, 1992).
Placebo treatments can lead to unwanted side effects or adverse drug effects. Just as with
positive placebo effects, nocebo effects rely on suggestion and expectation of adverse or
weak results. For example, in one study that investigated the way that information is
presented to patients in the context of influenza vaccination, framing the risk of side
effects negatively (as the percentage of people who experience a side effect resulting
from the vaccination) versus positively (as the percentage of people who don't experience
a side effect), increased the presence of both side effects and work absenteeism after the
immunization (O'Connor, Pennie, & Dales, 1996). Also, side effects reported from a
placebo increase with increasing dosage of the placebo (Pogge & Coats, 1962).
One tricky issue arising from this problem is how physicians and pharmaceuticals should
present risks to patients. Naturally, people must be informed about risks in order to make
decisions, but knowing too many details about risks, or learning about them about them
in emotional ways, may increase the likelihood that the medication will not be tolerated
by the patient. This question is related to philosophical issues in bioethics and informed
consent.
In the bioethics literature and the Declaration of Helsinki, the three central concepts are
respect for persons, beneficence, and justice ("Declaration of Helsinki (1964)," 1996).
The American bioethics community has put a particular focus on respect for persons,
which as been taken to mean informed consent. However, less effort is put into
understanding the optimal way to present informed consent information to patients to
ensure A) appropriate understanding and B) avoid undue anxiety, possibly leading to
increased nocebo effects.
One study showed that patients who were given an informed consent document that
detailed the possible risks, versus one that didn't go through the specific risks, increased
patient anxiety as reported on the Spielberger State-Trait Anxiety Inventory. Perhaps
even more worrisome, more people needed anxiolytic as administered by a nurse blinded
to the subject's condition in the study(Goldberger, Kruse, Parker, & Kadish, 1997). This
is worrisome because of the possibility of increasing side effects by highlighting possible
negative consequences. Also problematic is that, given the option, people will generally
opt to receive more information even when it is not in their best interest because of
people's inability to forget or discount information they have previously learned
(Camerer, 1989). In the same study, subjects were asked afterwards how satisfied they
were with the informed consent document they had received. The people who were
given the detailed risks were happy having received those details, but the people who
didn't get those details were also satisfied. They did not say they wished they had more
details.
The philosophical issue of respect for persons is an important one, but it is also
something that should be debated with a full understanding of where a narrow focus on
informed consent as a panacea can go wrong. Without resorting to the severe paternalism
that casts such a shadow over medicine of the 1950s and 60s (Vinar, 1969), it should still
be possible to empower people by crafting consent forms in such as way as to provide
them with risk and benefit information in the way most beneficial for their own cognitive
processing and use, and not merely using informed consent forms as an afterthought, or
worse, as merely legal protection.
Physiology
A misconception about the placebo response is that only 'imagined' symptoms can be
alleviated by a placebo. In fact, placebos work by engaging the body's own biochemical
healing systems. In placebo analgesia, incoming sensory information combines with
expectation in the brain to shape the experience of pain (Koyama et al., 2005). fMRI
studies show that placebo analgesia is related to decreased brain activity in pain-reporting
regions of the brain, including the thalamus, insula, and anterior cingulate, as well as
increased activity in the prefrontal cortex, implying that the experience of pain is being
altered (Wager et al., 2004). Many of the body's hormones and neurotransmitters affect
healing and may be implicated in placebo responses. It is known that placebo analgesia
is mediated at least in part by endorphins effect on the p-opioid system, a pain and stress
inhibitory neurotransmitter system. As another example, a recent paper by Benedetti and
Colloca reviews how anxiety may increase pain-related nocebo effects by the activation
of the cholecystokininergic (CCK) system, which facilitates pain transmission (Colloca &
Benedetti, 2007). In this manner, placebo effects reflect a fascinating interplay between
the psychological and the neurological. Other placebo effects (non-analgesia related)
work through different neural mechanisms (Fricchione & Stefano, 2005) (Pacheco-Lopez,
Engler, Niemi, & Schedlowski, 2006) (de la Fuente-Fernandez et al., 2001) but the
current discussion will focus only on pain.
The question of why some individuals demonstrate stronger placebo effects than others
has long been a research topic, and in fact for several decades clinical trial researchers
attempted to use personality factors to exclude 'placebo responders' from trials, to
seemingly increase the drug effect. However, personality factors were never found to be
reliable for this purpose, and it is now believed genetically determined variation in opioid
response may be a large player in interpersonal variation (Ikeda et al., 2005).
Additivity
It should be clear by now that 'the placebo effect' is not restricted to inactive placebos.
Many medical treatments act in two ways concurrently. The first is the way described in
the relevant pharmacology or surgery textbook for that condition, and the second is the
placebo effect. Both of these effects are mediated biochemically, and both of these
responses in conjunction with each other are responsible for the improvement seen after a
medical treatment. Many researchers believe that a significant portion of the effects of
medicines, from anti-histamines to blood pressure drugs, are due to this second effect
(placebo). For some types of treatment, expectation may even make up the majority of
the effect; researchers have determined that of the six leading anti-depressants,
approximately 80% of their effect was duplicated in placebo control groups (Kirsch et al.,
2008), (Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008).
The placebo effect is generally considered to be additive with non-placebo drug effects.
This is in fact the underlying assumption of all clinical trials, since the drug effect is
taken to be the difference between the placebo and active groups. Therefore the total
effect of a medical treatment can be thought of schematically as the sum of the non-
placebo specific effect and any positive placebo effects, minus any nocebo effects
(Kaptchuk et al., 2008).
This is not necessarily an endorsement of using pure-placebo treatments, especially
because many such treatments' placebo benefits may be overshadowed by risk. Blood-
letting or mercury-based medications may have had important placebo effects, but their
danger outweighed it. Similarly some placebo treatments could contain other risks, and
even when they don't, there are ethical questions involved in prescribing placebos. In
addition, it prescribing placebos becomes a known practice, this could introduce doubt in
treatments and reduce placebo effects. Therefore, the relevant question is to understand
how to enhance the placebo component of a treatment for overall improved medical
outcomes.
The placebo effect in clinical trials
As mentioned earlier, the 'gold standard' of modem medical research is taken to be the
two-armed blinded trial consisting of a placebo and active condition. The role of placebo
effects in clinical trials is not as simple as is sometimes assumed because of the fact that
placebo effects are not constant background noise. One major issue is that clinical trials
inform patients that they may not be receiving the real treatment, and that 50% of them
will receive the placebo. This information is believed to alter subject response to the
treatment by reducing placebo effects through encouraging doubt. One study by Kirsch
and Weixel gave participants decaffeinated coffee, telling them either that there was a
50% chance of them receiving placebo or active caffeine (mimicking double-blind
conditions), or telling them that they would receive caffeine (deceptive condition). The
two conditions led to significantly different results, with only the deceptive condition
leading to an increase in pulse rate (Kirsch & Weixel, 1988). In double-blind clinical
trials, the placebo effect may be so significant that the most relevant discriminating factor
between subjects is not what group they were assigned to, but rather what group they
have guessed they are in, making perceived group assignment a very relevant factor to
attend to (McRae et al., 2004) (Bausell, Lao, Bergman, Lee, & Berman, 2005).
In contrast to clinical trials, many experimental trials use deception and do not tell
subjects that they may receive a placebo. The American Psychological Association has
specific guidelines for when research may use deception, mandating that the study must
have value that cannot be learned without deception, and that the subject must be
'debriefed' with the truth at the end of the research ("The Ethical Principles of
Psychologists and Code of Conduct," 2003). However, deception is typically not
appropriate in a clinical setting. Another option that avoids deception is to use the hidden
administration of a drug. The patient consents to getting the drug, but is not aware of
when. By administering the drug through an already-existing intravenous catheter, it is
possible to examine the effects of the drug independent of placebo effects (Kirsch, 2003).
Pain
Strong and clinically relevant placebo effects have been studied in many conditions, as
discussed earlier. The best-studied of these, however, is pain. Placebo analgesia is
probably the most well-known and understood placebo pathway, and as early as the
1970s researchers were coming to understand the importance of endogenous opioids in
creating placebo analgesia by observing that the opioid antagonist naloxone could
partially prevent the placebo response (Grevert, Albert, & Goldstein, 1983), (Levine,
Gordon, & Fields, 1978).
The laboratory experiments discussed here focus on placebo analgesia for several reasons.
First, it is the best studied placebo effect, and the one for which the neural mechanisms
are best understood. Secondly, it is a placebo effect that can be studied in healthy
volunteers in a non-clinical setting, which facilitates the experimental process and avoids
the risks and challenges in experimenting on a population with an illness or disorder.
The difficulty in studying pain, however, is the same difficulty faced by clinicians; it is
difficult to judge the physical pain of another person. The most relied-upon method to
date is self-rating scales. In clinical settings these ratings scales come in a variety of
forms, such as drawings of faces with varying levels of discomfort. In experimental
settings the most common scale is the visual analog scale, consisting of a simple
horizontal line. The scale is sometimes 100mm in length, and the ends are usually
marked by words, such as "no pain at all" and "extreme pain." Typically the line is not
divided up by tick marks, numbers, or other markers (Price, McGrath, Rafii, &
Buckingham, 1983).
Since healthy volunteers are used for experimental purposes, such as the assessment of
analgesic products and pain-management techniques, researchers must be capable of
inducing pain during a study. There are a number of validated methods for experimental
pain. One of these methods is electrical stimulation (electric shocks). These shocks are
commonly delivered either to intact skin, purposefully damaged skin, or the tooth pulp.
The advantage to this method is that shocks are brief and transient, so that a number of
shocks, at different intensities, can be delivered over the course of an experiment.
Electric shocks do have some disadvantages. The most important of these, argued by
some researchers, is that this type of pain may not physiologically mimic natural pain
(Handwerker & Kobal, 1993), (Staahl & Drewes, 2004), (Bromm, 1985). Another
challenge of electric shock pain is that the subjective intensity of the pain may not be
entirely linear with increasing voltage; as voltage rises, a person's ability to discriminate
between different intensities decreases (B. Jones, Planas, & Anuza, 1982). NSAIDS are
not believed to have any effect on electric shock pain, although opioids may (Parry,
1979).
Another common method is the 'cold pressor' test. The cold pressor test is considered to
be a good model of chronic pain, and is quite simple in principle. The experimental
subject immerses their hand in cold water for a short period of time. Researchers study
the amount of time the subject is able to keep their hand in the water and/or self-ratings
of the pain during that time. There is relatively little standardization in the details of the
methodology across studies; the water temperature is generally between 1 and 7 degrees
Celsius and the length of the test is generally between 1 and 5 minutes (Mitchell,
MacDonald, & Brodie, 2004). It is preferable for the water to be circulated during the
test to provide constant water temperature, but this is not always done in practice.
Other methods of experimental pain induction include needles, mechanical pressure, heat,
and focused laser beams. All of these methods are frequently used, and there is not one
single method that enjoys a monopoly. The methods are analogous to different types of
natural pain, with shock pain belonging to the acute pain categorized as 'first pain' and
cold pressor pain being the more chronic 'second pain,' which are represented differently
neurologically (Ploner, Gross, Timmermann, & Schnitzler, 2002). In the experiments
below, shock pain and cold pressor pain are used.
Price-Quality Assumption
Traditional models of economics posit that consumer utility from a good or service is
determined accurately by each individual consumer. The consumer calculates how much
utility they will receive from a T-shirt, apple, or scuba diving class, and then accepts the
transaction if the seller price is below their reservation price. In this model the demand
for a product should be independent of the actual utility given by the product, and higher
price should be associated with lower demand. In contradiction to theory, though,
business and economic researchers are aware of anomalies in the typical shape of demand
curves. Specifically, higher price is sometimes associated with higher demand, not lower.
Research over the past several decades has examined this phenomenon and determined
one major reason is that individuals sometimes use price information as a proxy for
quality. In other words, price information may be used as a heuristic by which people
infer the relative merit of a product or service, be it familiar or unfamiliar (Rao, 1989).
Considerable research has established that people quite often perceive price-quality
correlations across a wide range of products. Quite frequently the perceived price-quality
assumption is actually not objectively accurate. In many different arenas of consumer
products, no correlation (or even a weak negative correlation) has been found to exist,
although price and quality move together more often in non-durable goods categories
(Riesz, 1979) (Wolinsky, 1983) (Lichtenstein, 1989).
This is a phenomenon with which many readers may be intuitively familiar, and yet there
are a number of potential reasons for this price-quality assumption. One cause may be
the information asymmetry inherent in the consumer-seller relationship (Akerlof, 1970).
Consumers are unable to have as much information about a product as does the
maker/seller of that product. Despite this disadvantage, consumers are still tasked with
the need to sift through their many choices and decide upon the best or most appropriate
purchase for their needs. This is an incredibly difficult task. Because many of the
important qualities of a product may not be obvious (for instance, longevity, the quality
of internal parts, customer service) companies have the need to "signal" quality in a
visible way.
The situation is reminiscent of quality signals in nature. When choosing a mate, naturally
an animal (in particular a female) desires a mate who will provide the best fitness to their
offspring, in order to protect their own genetic contribution, but quickly sizing up the
genetic fitness of a potential mate is not easy. Biologists and zoologists believe that
apparent handicaps (heavy, bright peacock feathers that use precious energy to maintain,
the building of ornate structures by bower birds who could otherwise be finding food,
etc.) may function as fitness signals since only a very healthy, skilled animal could
maintain these features or behaviors (Iwasa, 1991).
Similarly, a high price should be a handicap for a product's sales in the traditional model
of economics. The fact that an expensive product is so pricey and still on the shelves
may signal to consumers that it must warrant that price and must have some significant
advantage over less expensive products. Higher prices may also serve as a signal that
more expensive materials or processes went into the manufacturing of the item.
Of course, in nature as in consumer products, not all signals are "honest" in reporting
their quality. A $1000 luxury purse may not genuinely be of much higher leather quality
or design than a $100 bag. (On the other hand, the consumer walking around with the
expensive purse may be doing her own value signaling!). The high price may merely
reflect high margins on the part of the retailer/manufacturer, or in other cases may reflect
high advertising and marketing costs. It may be argued that rationally, intense
advertising campaigns should decrease a consumer's expectation for a product as it
relates to price, since one can logically infer that at least some of that its price must be
paying for marketing. However this effect does not generally seem to be the case, and
billions of dollars continue to pour into advertising for luxury and midrange products.
Instead, advertising and marketing have the power to enhance consumer perceptions,
perhaps creating in this way self-fulfilling prophecies for price-quality assumptions. For
instance, a recent study has shown that increasing the stated price of a wine increased not
only subjective reports of its taste, but also fMRI activity in the medial orbitofrontal
cortex, which is believed to be related to experienced pleasantness (Plassmann,
O'Doherty, Shiv, & Rangel, 2008). And if price can increase perceived utility in this
way, then in reality it does have value beyond that discovered in objective, price-blinded
quality studies. Especially relevant to the current research, if price can increase expected
value, then in the case of medical products, it may be able to modify not merely
perception, but the actual product performance via the placebo response.
There has previously been very little research aimed at directly testing the hypothesis
discussed above, that prices can impact the direct effect of a medical product by
modifying the placebo effect. One study by my colleagues, which used the energy drink
SoBe, found that a price difference could impact the placebo cognitive benefits of the
drink (Shiv, 2005). Another thought-provoking paper found that that the price of a drug
could predict effects on health-related quality of life; the higher the average wholesale
price, the better the quality of life, regardless of what specific condition it was for. The
researchers were unable to determine the cause of this strange relationship but were
surprised at its strength. One possible explanation, according to the authors, was that
pharmaceutical companies might price products in accordance with their benefits on
health-related quality of life. Another possible argument would be that it might have to
do with the research and development costs of the pharmaceutical company, and that
higher R&D costs might lead to both the higher prices as well as apparently superior
efficacy. However, there are multiple problems with either explanation, since pricing is a
complex decision based in a dynamic marketplace that cannot be made directly based on
R&D costs or clinical trial efficacy (Murawski, 2003). On the other hand, this research
could potentially support the hypothesis presented here, that price may have a direct
effect on medical outcomes.
It is noteworthy to point out that price is not the only important signal of quality.
Another is the country of origin of a product. Because global trade is a vitally important
issue for all economies, there is a need to understand consumer attitudes towards foreign
and domestic products. In particular, a large body of research has found that consumers
in developed countries display a preference for domestic products. "Made in USA" (or
other home country) may serve as a quality cue and/or as a 'low-risk' cue. The concept
of consumer ethnocentrism comes into play when consumers attach additional value and
quality judgments to domestic products (Shimp, 1987). Research on consumer
ethnocentrism has suggested that foreign manufactures might want to downplay their
foreign origin (Watson, 2000), although this is not always possible. In the United States,
American-made products are sometimes considered preferable both because of the
economic benefits to the country and because of perceived superior quality in certain
categories.
In contrast to this there are countries whose products consumers actively avoid. Over the
past few years and particularly in 2007, many Americans, including the media, have
wondered if the Unites States should ban food and drugs from China (Tonelson, 2007).
This followed scandals involving tainted pet food (which caused a number of feline
deaths), toothpaste, and lead-painted children's toys (Barboza, 2007), (Lipton, 2007),
(Bogdanich, 2007). Because of these starkly contrasting opinions of products from
different countries, and in particular the United States versus China, consumer
ethnocentrism has the potential to be a relevant issue in international trade and a source
of unexpected economic perturbations. Accordingly, the hypothesis is that: consumers
would place greater value and quality signals on an American product, and that this effect
might also modify placebo responses.
Price and country of origin are not the objectively best ways to make an assessment of
quality. Because it is not possible for the average consumer to consult an informative and
unbiased source of information like Consumer Reports for every minor purchasing
decision, heuristics and rules of thumb are useful ways to help people make decisions.
Even if these heuristics fail us at times, they at least allow us to decide upon something
quickly and accurately on average. It is only those rare instances where the failure of our
heuristics lead to some significant unwanted outcome that we must re-examine what rules
we rely upon for our expectations, perceptions, and decisions. In the case of medical
therapies, unwanted outcomes would include poor choices of the best treatment as well as
reduced efficacy of a treatment.
Laboratory Experiment 1
Veladone Experiment Methods
To design a laboratory experiment to determine if marketing factors could module
placebo effects, it was important to take great care in creating the right atmosphere and
environment, and to keep procedures very consistent across subjects. For the initial
laboratory experiment, it was decided to examine both a difference in price as well as a
difference in country of origin, on the efficacy of a placebo analgesic.
Subjects and Recruitment
82 subjects participated in the experiment. Potential candidates were excluded if they
had a history of cardiac problems, epilepsy, diabetes, or were pregnant. Participants were
between the ages of 18 and 65 (mean age was 30+11.84) and taking no pain medication
at the time of the experiment. Participants were not selected on the basis of gender, and
31 of the 82 subjects were male.
The subjects were recruited with an online advertisement explaining that they would
receive moderate electric shocks to their wrist and fill out a questionnaire of their past
painful experiences. The experiment was described as a study of how an individual's
past history of painful experiences related to their current response to pain-reducing
medication and painful stimuli. However, there was no active selection based upon
subjects' past history of pain.
Procedure
There were two conditions in this study, price and country of origin. Each of the two
conditions contained two levels; price was either $2.50 per pill, or discounted from $2.50
to $.10 per pill. Country of origin was either American or Chinese. This information
was presented to the subjects both verbally and in written form in a brochure about a
medication, which was invented for the experiment and actually a placebo. The
brochures also contained other information about the purported medication, Veladone Rx,
such as its indication (moderate pain, such as after dental surgery), the fact that it worked
quickly, and potential side effects (such as nausea and dizziness). Using an invented drug
avoided confounds based upon a subject's pre-existing relationship with a medication.
Four brochures were created which were identical except for the price and country
information. Participants were randomly assigned to one of the four groups. The
experiment room was carefully set up to be moderately medical in character, with such
props as biology books on shelves, a lab coat for the experimenter, and a blood pressure
test.
Because placebo effects are so sensitive to the opinions and knowledge of a medical
practitioner, the experimenter was blinded by use of a confederate. Participants were
familiarized with the study procedure by the experimenter, who was introduced as a
graduate student in pharmacology. They then spoke with a "representative from the
pharmaceutical company," who gave them the brochure about the medication as well as a
promotional pen with the drug name, and answered any questions they had about the drug.
The experimenter left the room during this time to maintain blindness. The pill was
explained by the confederate to be a newly-FDA approved, effective analgesic pill that
might modify their pain experience. It was described to cost either $2.50 per dose or to
be discounted from $2.50 to $0.10, and to have been manufactured either in North
Carolina or in China. Subjects were randomly assigned to one of the 4 groups (high price
America, high price China, low price America, or low price China). The assistant
confirmed that subjects had attended to the target information by administering a short
manipulation check quiz on information contained in the brochure, including the target
information of price and country. If a subject made an error on the answers to the two
pieces of target information, they were corrected before moving on. The confederate
then left and the experimenter returned.
After subjects were familiarized with the procedure and medication, they were introduced
to the stimuli, a series of 100ms electric shocks applied to the volar surface of the right
wrist using an SD9 stimulator (Grass-Telefactor, West Warwick, Rhode Island, USA).
The area on the wrist was first cleaned with alcohol and a conductivity-increasing gel was
used. To calibrate stimuli intensity to the appropriate range for each subject, subjects'
maximum tolerance was determined to be the voltage they rated as an 8 out of 10 on a
scale ranging from "no pain at all" to "intense pain." The experimenter started at 10 volts,
which was imperceptible to most subjects, and increased voltage intensity until
participants verbally rated that pain as an '8'.This was the highest intensity subjects
received at any point during the experiment. The calibration and shock methodology was
modified from that used in Berns et al 2006 (Berns et al., 2006).
Subjects next received a series of shocks, which were all possible shocks between 10
volts and their calibrated maximum tolerance in 2.5- V increments. Therefore the total
number of shocks depended on subjects' calibration and never exceeded the calibrated
maximum; mean number of shocks per round was 20.72, and a number of these tended to
be below the subject's pain perception threshold. Subjects rated the perceived intensity of
the shocks on a computerized visual analog scale anchored by the words "no pain at all"
and "the worst pain imaginable."
This first round of stimuli was followed by subjects' receiving the placebo, which was a
small red pill suggestive of commercial over-the-counter pain relievers. After a waiting
period of 15 minutes to give the medication time to 'take effect,' a second round of
shocks commenced analogous to the first round. During this waiting period, the wrist
electrode was removed, but its exact location was drawn on the participant's arm so that
it could be replaced in the same position. At the conclusion of this waiting period, the
VAS rating procedure was repeated. The random order of voltages in the first round was
precisely replicated in the second round, such that if the first shock of the first round was
20 volts, the first shock of the second round was also 20 volts.
At the end of this session, subjects completed a questionnaire regarding their attitude
towards, and history of, painful experiences. Then subjects were thoroughly debriefed
regarding the true purpose of the study.
Procedure Subject
explained to Experimenter ingests
subject by returns; performs pill; 15
experimenter calibration min wait questionnaireI I I I I I I
1 round 2nd round debriefingExperimenter leaves; stimuli stimuli
'drug representative'
introduces medication
Figure 1: The experimental timeline of the Veladone experiment.
Veladone Experiment Results
The main unit of analysis in the analysis of the Veladone data was the difference scores
for each participant- the change at each intensity level between the first round of shocks
and the second round. Studying only the between-condition difference of the difference
scores eliminated irrelevant sources of variance from consideration. (This is important
because the difference between round 1 and round 2 is not uniquely a placebo effect, as
additional factors such as demand effects and habituation could be involved. The
difference between conditions, however, will only be affected by the price or country
manipulation). The VAS ratings were simply converted to a 100-point scale, and the
second round was subtracted from the first round.
Mixed-Effects Model
A linear mixed-effects model was fit with subjects as a random factor and all other
variables as fixed effects. Neither age nor gender were found to be significant factors
and so were excluded from subsequent analyses. The voltage of each difference score
was entered into the regression to control for the physiologic differences in pain sensation
at different voltages; this factor was significant, as predicted. Overall, 73% of subjects
rated the shocks to be on average less painful during the second round. However the
focus was not on this reduction but rather if manipulation of price and country of origin
would influence the placebo response.
As is expected for physiologic reasons (B. Jones, Planas, M., Anuza, T., 1982), the
Voltage level of each shock significantly affected the difference score ratings (p<.0001).
The Price manipulation was also significant, as expected, and this is further discussed
below. The Country manipulation was significant, but in an unexpected direction, and as
discussed in a later section, this is actually due to the significant interaction with
Ethnicity (Asian versus Non-Asian). The factor "Pain Day" in the table relates to the
subject reporting having had pain on the day of the experiment unrelated to the electrical
shocks, and is also further discussed below.
Value DF t-value p-value
Intercept -13.41 1040 -1.21 .228
Voltage 1.90 1040 5.34 .000
Price(Low) -25.00 65 -3.22 .002
Country(China) 41.84 65 2.84 .006
Ethnicity(Non-Asian) 28.27 65 2.79 .007
Pain Day(pain-free) -8.70 65 -1.09 .282
Price(Low)*Country(China) -9.45 65 -1.03 .308
Country(China)*Ethnicity(Non- -36.67 65 -2.80 .007
Asian)
Price(Low)*Recent pain (no 35.12 65 3.65 .001
pain)
Country(China)*Recent pain -4.92 65 -0.51 .612
(yes pain)
Table 1: The results of the mixed-model regression show the significance of Price, Country, Ethnicity,
Voltage, and the interactions between Country and Ethnicity and Pain Day and Price. Note that this
analysis does not include those 8 subjects who due to a clerical error did not respond to the 'recent pain'
question on the questionnaire.
Price Manipulation
A chi-square test showed a significant difference between the number of people
experiencing an overall reduction in pain reported, versus an overall increase in pain
reported, between rounds. In the non-discounted condition, 78.1% of the participants
experienced a mean pain reduction after taking the pill, versus 56.1% in the low-price
(discounted) condition, a significant difference per 2-tailed chi-square-analysis 2(1,
N=77) = 6.0, p<.05). Because some research suggest that stronger pain may be
associated with stronger placebo responses (Harrington, 1999), the most painful 50% of
shocks was also tested, and the same pattern was found; 80.4% of high-price condition
participants experienced mean pain-reduction versus 53.7% in the low-price condition.
Again, 2-tailed chi-square-analysis is significant 72(1, N=78) = 5.7, p<.05).
Likewise, when considering the data for each stimulus intensity, 26 out of the 29
intensities showed greater pain reduction was greater for the high-priced than the low
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Figure 2: Mean difference in pain ratings, after vs. before placebo, by voltage intensity. The table depicts
the intensity of the shocks (top row), the number of observations in the high price (2nd row) and low price
(3rd row) conditions, and the significance level of each difference (bottom row).
Country Manipulation
Contrary to the original hypothesis, the America condition was not superior the China
condition. In fact, overall the China condition produced greater analgesia. However,
when this is broken up by subject's ethnicity, a very different picture emerges. An
interaction was found between country of origin and the ethnicity of the subject.
Ethnicity was taken to be a very rough measure of Asian (including both Asian-American
and Asian) versus non-Asian ethnic background. The average mean difference score for
Asians in the United States condition was -5.8, indicating that their pain ratings were
actually higher in the second round after receiving the placebo, whereas in the China
condition the average mean difference score was 22.17. This is a significant difference,
(clustered t-test p<.001). Among Non-Asians, however, there was no difference for the
country factor (M-United States 9.62, M-China 13.16, clustered t-test p=.352).
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Figure 3: Country of origin has no effect on pain for non-Asians, but the China condition is significantly
better than the American condition among Asians.
Price interacts with subject's other pain experiences
In the questionnaire administered after the second round of stimuli, participants were
asked if they had experienced pain (even mild pain such as a headache or a sore muscle)
during the day of testing, before the experiment. Participants' response to this "recent
pain" question significantly interacted with the price factor, such that participants
experiencing recent pain responded much more strongly to the price manipulation and
reacted more negatively to the discounted treatment (see figure). The explanation of this
effect will rely on future research, although one hypothesis is that these individuals
experiencing recent pain also had more salient, recent experience with taking analgesic
medications. Subjects who report experiencing pain other than the experimental
procedure the day of the experiment, or the month prior to the experiment, show a
significantly different response to the two price levels (p<.05 ) than do subjects reporting
no pain in this time frame (p=.237). This interaction is significant, p<.001. Subject's
self-report of painful experiences during their lifetime, however, does not interact with
response to the Price factor.
I I
There are several interesting explanations for these results. It may be that individuals
who have experienced recent pain also have more experience taking analgesic
medications, and have been convinced of a price-efficacy correlation in the real world. It
is also possible that part of this effect is mediated through another factor, that of
perceived pain tolerance. Subjects were asked to indicate how their pain tolerance
compared with other individuals, and we found a significant correlation between
experiencing recent pain and considering oneself to have an above-average pain tolerance
(r=.399, p<.001). This may imply that experiencing pain can influence an individual to
judge themselves good at coping with pain. Interestingly, this perceived pain tolerance is
uncorrelated with objectively measured pain tolerance (the calibration procedure of the
experiment), (r=.068, p=.543). An individual's perceived pain tolerance may affect
placebo effects via its effect on the affective characteristics of pain for that person and
their emotional state, which are known to moderate placebo responses (Zubieta, Yau,
Scott, & Stohler, 2006).













Figure 4: Among people experiencing no recent pain, there is no clear effect of the discount manipulation.
Among people experiencing pain the day or month of the experiment, the undiscounted pill is significantly
better than the discounted version.
Veladone Experiment Discussion
The results of the Veladone experiment, particularly the Price manipulation, are striking.
The effectiveness of the price manipulation is particularly thought-provoking given that it
was relatively subtle and naturalistic; Price was merely one piece of information out of
many provided to the subjects, and it was not directly related to drug effectiveness as, say,
mode of action would be. Many studies that aim to invoke placebo responses rely on a
combination of strong verbal suggestion ("this is a powerful analgesic") and direct
experience of the placebo's effectiveness (i.e. by turning down the intensity of the stimuli
to make it appear the placebo is working) (Petrovic, 2002). Yet the current results
suggest that placebo effects may be manipulated by factors that are considerably more
indirect and that are naturally found in consumer's experience with medical products. In
addition, there are ways in which the expectancy manipulation used here is considerably
weaker and than the marketing and pricing issues that typically come into play in
consumers' lives. Not only were our subjects merely told about the price of the drug, as
opposed to actually paying for it, but they did not experience the massive amount of
advertising that often accompanies pharmaceuticals in the real world.
It is worth highlighting that it is likely not the absolute price of the drug behind the
reduction in efficacy, but rather the impact of the discount on subjects' evaluations of the
medication. In the absence of an explicit discount, moderately low prices will probably
not have a large negative effect simply because the average consumer (and physician, for
that matter (Allan, Lexchin, & Wiebe, 2007)) has only a vague idea of appropriate prices
for medications. However, while absolute value evaluations are difficult to make, the
relative evaluation of normal price versus discount prices is much more obvious, and it is
this relative evaluation that puts the discounted product in a negative light (Ariely, 2003).
One might wonder also what the effect would be when the consumer is provided with a
coherent and reasonable reason for a certain price discount; would this reduce the
negative effect of discounting? This remains an open question, although the results of the
past study that used SoBe suggest that this would not counteract the nocebo effect. In
that study a logical explanation for the discount (being told that it was due to being an
institutional bulk purchase) did not protect against the negative effect of the discount
(Shiv, 2005).
Because relative discounts may be more relevant than absolute prices, the implication is
not that pharmaceuticals should be priced exorbitantly high to produce maximal effects,
but rather that high baseline prices coupled with discount prices may lead to some loss of
efficacy. It is worrisome to consider that this is precisely the situation for low-income
and elderly individuals who obtain their prescriptions through the patient assistance
programs run by most major drug companies for people without health insurance and low
income.
The fact that the country of origin manipulation did not fit the hypothesis is interesting.
The lack of any effect among non-Asians may relate to the lack of any explicit relative
evaluation for this condition. Unlike in the discount condition, where attention was
drawn to the difference between the full price and discount, in the China condition there
was no mention of, say, a move to outsource production from the United States. Another
reason for the lack of difference may simply be that people did not have a uniformly
negative quality evaluation of products from China, as this was before the string of
China-related quality control scandals. An informal survey of undergraduates at the time
corroborated that idea; they said that they would not have any problem with medicine
from China but might have some concerns if it were from a country less well known for
imports, such as Thailand or the Philippines. In fact, subjects showed great variability in
their opinion of Chinese drugs, and much of this opinion was not negative. Some
mentioned, for instance, that they had to be the same as American drugs since it was FDA
approved. Other said that since traditional Chinese medication was effective, this product
would be too. Another issue might be that even when consumers place more value on a
product from the United States, it does not necessarily mean that they believe it to be of
higher quality (the greater value could come in some other form, such as supporting
American jobs).
Laboratory Experiment 2
Significance of Brand Name
Brand as cultural information
Brand names are cultural information and in essence a fundamental part of the ritual
surrounding a modem medical object (Greenslit, 2007). Brands touch upon quality
signaling, issues of personal identity and choice, nostalgia, and group affiliation. It is
also known that brand name is able to strongly affect people's perception. One well-
known investigation of the role of brand name on perception involved Coca-cola and
Pepsi-cola, for which people regularly express a preference irrespective of their very
similar composition. Subjective taste tests of unlabeled Coke and Pepsi showed equal
preference for each beverage, but a taste test with the Coke label showed a bias for Coke
in the population studied. The neural correlates of this brand-information-modified
sensory perception were then demonstrated with fMRI. While in the scanner, subjects
drank Coke or Pepsi while possessing or not knowledge of which brand it was, and brand
knowledge (at least of Coke) was associated with neural response in the dorsolateral
prefrontal cortex, separate from the sensory perception of the experience in the
ventromedial prefrontal cortex (McClure et al., 2004). Accordingly, just as other
informational cues and rituals are important in the placebo response, it seems quite
possible that brand would be too (Kaptchuk, 2002).
However generic products are of increasing importance, especially in the arena of
pharmaceuticals. The percentage of prescriptions that are generic in the United States has
been growing over the past decade to the 2007 rate of 67.3% of all prescriptions
(Koroneos, 2008). When it comes to generic medicines, however, quality may be
questioned.
The FDA states that generic drugs are exactly equivalent to their brand-name
counterparts. Specifically, the FDA states that a generic drug "is a copy that is the same
as a brand-name drug in dosage, safety, strength, how it is taken, quality, performance,
and intended use (FDA, 2008)." Despite this official position, physicians and patients
alike display uncertainty about the equivalence of generic and branded medications
(Meredith, 2003), (Pereira et al., 2005), (Hassali, Stewart, & Kong, 2008), (Banahan &
Kolassa, 1997),(Kjoenniksen, Lindbaek, & Granas, 2006),(Kirking, 1990), (Himmel et al.,
2005)
Trust in generic medications is known to be less than absolute. For instance, documents
exist to instruct pharmacists in how to discuss the issue with patients and educate them on
the therapeutic equivalence of generic medications, when the pharmacist but not the
patient assumes equivalence (USPharmacist, 2007). And for some conditions, such as
epilepsy, generics are not recommended even by their official organizations
(Epilepsy.Foundation, 2008). There are even reported cases of such intense distrust of
generic medications that it results in "somatic" disorders, such as the case study of a
woman believed herself allergic to all generic medications and became acutely itchy upon
taking any kind of generic medicine (Brennan & Lee, 2004). However, low-to-moderate
distrust of generic medications, as a function of its pervasive nature, seems even more
worrisome.
One ethnographic study in France found that a number of individuals spontaneously
expressed their ambivalence and uncertainty, and even suspiciousness, towards generic
medications. People expressed disbelief that generics and brand-names were really
identical, even if they knew they were and had been taught by the pharmacist or doctor
that they were identical. One man was quoted as saying, "it's maybe the same molecule
but it's less... strong!"(Sarradon-Eck, Blanc, & Faure, 2007).
The belief that a quality difference exists between brands and generics may also be
promoted, logically enough, by brand-name pharmaceutical companies, such as in the
advertisement below, or as Eli Lilly did on their website after the 2000 introduction of
generic fluoxitine (Greenslit, 2007).
Graphic 1: This Valium ad encourages doctors to demand branded medications.
This thesis does not take a position on whether or not there are truly no biologic
differences, in any circumstances, between branded and generic medications.
The truth about generic drugs is likely to be more nuanced, such that certain medications
are affected by differences in binding agents or particle sizes, resulting in therapeutic
differences, while in general generics are very acceptable substitutes. What is relevant for
this document, however, is the belief that generics may be inferior, even in situations
where no relevant bioavailability or other differences exist (Meyer, 2001) because lack of
trust in a generic product might run the risk of reducing the placebo response to that
product. Actually, this issue of reducing the strength of the placebo effect is relevant
both in situations where the generic is factually equivalent as well as when it is not,
although in the latter situation any placebo benefits might well be outweighed. Therefore
the rest of this discussion will focus on situations where the two formulations are
therapeutically equivalent from a biological point of view.
Ambivalence towards generic medications by patient and physician comes in differing
degrees. Some people may hold explicit negative views towards all or specific generic
medications. However, weaker, implicitly held beliefs of moderate doubt may be very
relevant as well.
Surveys on Attitudes towards generic medications
A survey was conducted on the MIT campus with 93 individuals (mean age 28.42 ±
11.92, 50 female). In this survey, respondents evinced moderate doubt in the idea that
generics and brand-name drugs are entirely equivalent. Given the questions, "are generic
drugs as effective as brand-names" and "are generic drugs made to the same standards as
brand names," the average participant response was a 5.7 and 5.3 respectively, on a 7-
point scale. While this difference is significantly different than a response of 4, or
entirely ambiguous (t(92)=14.75, p<.001; t(92)=10.26, p<.001), it is also significantly
different from 7, or complete confidence (t(92)= 11.29, p<.001; t(92)=13.40, p<.001).
Because attitudes towards generic medications are particularly relevant among geriatric
populations, a similar survey was conducted at an AARP event. 56 responses were
collected, age 63.2 ± 8.77. 41 were female, 8 male, and 7 did not indicate gender.
Although there was high New England/Northeast representation, nearly 50 zip codes
were represented. The respondents took an average of 3.45 ± 2.54 prescription
medications each, however it should be noted that this does not represent population
values as recruitment was biased towards individuals who took at least one medication.
(Only 4 respondents took no medications). Respondents indicated how many of their
medications were generic. 44.7% of prescription medication were generic, but there was
considerable variability (standard deviation is ±34.8 percentage points). 25% of people
take took at least one generic medication, 21% said 50% of their medications are generic,
and 15% responded that 100% of their medications were generic. In the AARP group,
the average response to the question about generic drugs being as effective as brand-
name drugs was 4.91 (again, on a 7-point scale), and the average response to if generic
drugs are made to the same standards as brand-name drugs was 4.82. Interestingly, this
means that the overall responses in the AARP group showed significantly more distrust
of generic medications than in the younger group. (For "effective," p<.001; for
"standards," p=.052).
Doubt in generic medications goes along with the intense importance of medicine. Given
that medications are intimately tied to both the duration of and quality of a person's life,
doubt in a generic medication may be likened to Pascal's wager, the 17th-century French
philosopher who argued that a person's best bet in life is to believe in god even if the
odds of his existence are exceedingly small. The argument goes that the reward for being
correct (heaven) is infinitely better than the penalty for being wrong (hell), and thus any
doubt whatsoever must lead to acting upon that doubt. Similar thought processes seem to
be in play regarding generic medications. Although a person may generally believe that
generics are equivalent, when the stakes are high (life), taking the generic is simply not
worth the risk. This may be an entirely reasonable response, and it indicates quite clearly
that doubt in generic drugs is rampant.
In fact, this is the type of response received in the questionnaire. Among those 27
individuals who did say they believed generics and brands were entirely equivalent (an
answer of '7'), all said that they would take a generic medication to treat a cold, but fully
52.2% said that they would not choose a generic medication to treat cancer. The same
results were found with other serious versus nonserious conditions. Across all the
respondents for 12 health conditions that ranged in seriousness, people said they would
take a generic for an average of 6 of them (50%). But, for the 6 conditions classified as
"serious," people would take a generic for an average of 1.8 of them (30%). Such a
response indicates that even people who logically believe in the equivalence of generics
and brands would change their outward behavior and choose the brand. If outward
behavior is changed, then it seems likely that there are reasonable seeds of doubt in the
person's mind that could influence the expectations and beliefs that are the core of the
placebo response.
Because of these trust issues revolving around generic medications, research is necessary
to determine if these beliefs can be responsible for negative health outcomes by
modulating placebo effects. On the AARP survey, respondents were asked about
experiences switching from the generic to brand-name version of a drug or vice versa.
33% of people indicated that had at least once switched from a generic drug to the
equivalent brand-name drug, and that on a scale of 1-7 in terms of being more satisfied
with the new (brand) drug, they averaged 5. On the other hand, 82.7% of people said that
they ever switched from a branded medication to a generic, and the average satisfaction
rating was only 4.09. This means that people were significantly less satisfied with a
medication change when they changed to a generic instead of from a generic (p<.05).
Qualitative Interviews
Nine qualitative phone interviews were conducted with individuals who responded to an
online advertisement for people who had experience with both brand name and generic
drugs, in order to learn about the kind of language that people use about brands and
generics.
A number of respondents with experience with both the generic and brand name of a drug
believed the two versions to have been equally effective for them. Interestingly, even if a
particular generic seemed to work, this did not mean that generic had the benefit of the
doubt. One 61 year old man who had been forced to switch from a branded to a generic
medication expressed his belief that generics could be, but were not necessarily, equal to
branded medications in the statement, "I took the precaution of calling their pharmacists
[to] give me the short course on generic versus brand name. [There are] different grades
of generics drugs, you know, and their particular pharmacy only handles the higher grade
that's passed FDA scrutiny."
This caution relating to generic medication was a recurring theme. Several people said
that they asked their doctor or pharmacist if taking the generic was okay. One 40-year
old woman discussed the fact that she usually takes generics, but that for her son she buys
only branded medications (OTC in this case), saying "I won't go generic with him."
Another woman stated that "I have complete faith in generics" but later mentioned that
"maybe the integrity of [brand-names] are superior."
Several respondents mentioned more active feelings against generics. One interviewee
talked about her husband's belief that generics will not work as well, which she attributed
to not being adequately informed on the subject. With regards to generic antidepressants,
her husband blamed any behavior change on the medication switch. Another, 60-year old
woman stated that she "feel[s] bias towards generics without really having facts." She
also stated that her endocrinologist had informed her that generics have worse quality
control. She discussed 3 medications that, for insurance reasons, she had switched from
the branded to generic form. For two of the medications, she stated that the generic did
not work as well as the branded version (and for one of these, the relevant professional
association has stated that generics are equivalent(AACE, 2008)), while the third
medication seemed to have the same efficacy in generic form.
Patient Education
Education of physicians and patients is sometimes discussed as the solution to inaccurate
beliefs about generic medications. In fact, survey respondents seemed to desire more
education. When asked, if "I know enough information about medicines to make a good
decision between brand-name and generic drugs" only 14.5% of the AARP group and
10.8% of the younger group "strongly agreed," and the average response was 4.5 and 4,
respectively. This confusion was also expressed by the fact that while the respondents
indicated a moderate distrust of generic medications, at the same time, they strongly
disagreed with the statement, "Price generally reflects the quality of a medicine, such that
a more expensive medicine is likely more effective than a cheap medicine," answering on
average 2.5 out of 7. People also disagreed to some extent to "I try to buy the brand-
name version of a medicine whenever possible," giving it 3.4 out of 7.
However, education cannot be considered a panacea because of the fact that rationally-
held beliefs may not override the power of emotional impulses when it comes to attitudes
towards generic drugs. Education may lead people to know that a generic is equivalent to
a branded medication, but it has a difficult task in eliminating all doubt.
It is also important not to prematurely believe that an educational process is complete. It
may be possible, after a discussion with an informed physician or pharmacist, to
successfully induce a patient to choose the generic medication. However, this choice,
made under some degree of pressure (however well-intended), can not be evidence that
the patient truly believes in the generic product.
Implication of distrust of generics
The debate over generic drugs has serious consequences. Prices for generic drugs average
30-80% less than brands, and the savings to the health care system of using generic
prescription medications are enormous. In one study, full use of available generic drugs
would have saved $5.9 billion annually in the United States (Haas, Phillips,
Gerstenberger, & Seger, 2005). As a result, it is clear that there are real reasons to
promote generic drug prescribing. And yet, if this is successful, the lack of trust
displayed in these products could have real implications for the placebo component of
their effects and potentially, real health implications.
To date, the only (known) published paper that considered the role of brand name on the
efficacy of medical products is a 1981 paper by Branthwaite and Cooper in the British
Medical Journal. In this paper, 835 women were given a painkiller, which was either
placebo or active aspirin, and was either a well-known branded or generic form. Over a
2-week period, subjects were instructed to use the tablets to treat any headache they
developed, and the researchers analyzed self-report of the efficacy of the medication.
This research found that more headache relief was provided by the brand-name than
generic versions. However, this research was limited in that it was relatively
uncontrolled. For instance, in this study subjects in the branded conditions reported more
headaches than subjects in the unbranded conditions, so the brand manipulation may have
had confounding effects on the decision to take a medication, rather than solely the
medication's effect (Branthwaite & Cooper, 1981). Consequently more research on the
topic is called for. A controlled laboratory study to do just that is described next.
Cold Pressor Experiment Methods
For a second laboratory experiment, the goal was twofold. First, the goal was to test any
difference brand-name versus generic medications on medical outcomes via a placebo
response. Secondly, the plan was to develop an experimental procedure that could act as
a platform for many future experiments. Ideally this platform would allow testing of the
placebo effect within an active drug effect. The shock procedure would not satisfy the
second goal since for the most part only opioid drugs are thought to have an effect on that
type of pain. There was also a consideration of using a lidocaine skin cream, which may
have effect on electric shock pain, however it was determined that since there is no
lidocaine skin cream with a well-known brand name, that this would not be the best
manipulation. On the other hand, oral acetaminophen has been shown to significantly
reduce pain from the cold-pressor test, although its effect may be modest and stronger
with dosages above that typically given (Yuan et al., 1998). Therefore the decision was
to use acetaminophen and the cold pressor test, in an effort to study a study a system with
a real but small drug effect. Such a system could be an ideal platform for future studies,
because a small drug effect could be manipulated by placebo manipulations, and would
not be so strong that it would have a ceiling effect on which brand or price could have no
effect.
For the cold pressor study, subjects were recruited by a posting to list-serves affiliated
with the university, meaning that a large percentage of subjects were undergraduates.
Subjects were, as before, told that the study had to do with how a person's past history of
painful experiences related to their current response to pain-reducing medications.
Eligible participants were people who did not report high blood pressure (because of the
potential of the cold pressor test to raise blood pressure), did not drink 3 or more
alcoholic beverages per day (because of the potential for liver disease, in which case
someone should not take acetaminophen), did not have any cardiovascular, pulmonary,
metabolic, or liver disease, and was not allergic to over-the-counter pain relievers.
Subjects were paid $30 for participation, and the entire experiment lasted under one hour.
Subjects gave informed consent for the procedure. The consent forms for the two
conditions differed by only one line: whether they said the subject would take
'acetaminophen' or 'Extra-Strength Adult Liquid Tylenol.' Neither statement involves
deception.
This study was run in an experimental room in the Media Lab. The room was set up with
the experimental apparatus and was otherwise bare, except for biology-related textbooks
on the shelves. The temperature in the room was slightly warm due to the heat output of
the cooling machine. 100 subjects were run by the primary experimenter and 33 by one
of two undergraduate assistants using the same experimental script.
In this experiment, subjects performed the cold pressor task two times, before and after
ingesting the medication. In order to be absolutely certain of therapeutic equivalence,
subjects were always given the same medication. This was extra-strength adult liquid
Tylenol, either in its original packaging or re-packaged into a generic pharmacy bottle
that simply read "acetaminophen." In this way there were no differences between the
medication given to subjects except for the presence or absence of a brand-name, as seen
in the photo below.
Graphic I: lylenol was presentea to suojects elmtner m its normal nqula, extra strength container or in a
generic pharmacy container reading "acetaminophen. Use as directed."
For the cold pressor task, subjects placed their hand in a small tub of water held constant
at 40 C by a Neslab R100 circulating water chiller. Subjects placed their left hand in the
water, with the water line coming up to approximately just past the knuckles. The
forearm rested on the rim of the machine to reduce muscle strain.
During the time that the subject's hand was in the water, they made ratings of their
discomfort on a tablet computer to their right. Every 10 seconds, a visual analog rating
screen appeared, anchored to the left with 'no pain' and to the right with 'extreme pain.'
Subjects made ratings each time that the screen appeared by dragging a slider which
defaulted in the middle, with a stylus, as seen in the photo below. Ratings on this visual
analog scale were later converted to a 1000-point scale for analysis.
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Graphic 3: The subject placed their left hand in the tub of cold water while using their left hand to make
painfulness ratings on a computer screen.
Subjects were instructed to remove their hand from the water when their discomfort level
reached a subjective 8 out of 10. If subjects never reached this level, they were
automatically asked to remove their hand from the water after five minutes as a
precaution against injury. The time until hand removal was recorded by the experimenter
with a stopwatch. Following removal of the hand, subjects made one final rating on the
computer, about their overall discomfort during the task. Towels were provided to dry
the hand.
After this first cold pressor task, subjects took the medication. Subjects were given
500mg in 2 tablespoons of the liquid Tylenol, which is the normal recommended adult
dosage, in a disposable plastic medicine cup. Half the subjects saw the liquid poured
from the normal Tylenol container, and the other half saw it poured from a generic
pharmacy container. The bottle was left in view of the subject for the entire experiment.
Subjects were also offered a cup of water along with the medication which most accepted.
(Note that although keeping the bottle in view of the subject during the experiment made
it impossible to blind the experimenter to the subject's condition, it was felt that this step
was necessary to remind subjects of the brand/generic condition, and the experimenter
was careful to remain silent during the cold pressor task to avoid biasing the results.)
Next subjects waited 20 minutes. (The onset of analgesia has been determined to be
somewhere between 15 and 90 minutes and it is known that onset time is shorter in an
effervescent solution than in tablet form (Moller et al., 2000) During the 20-minute
_ __
waiting period, subjects simply did whatever they wished, usually reading or checking
email. Following the waiting period, the cold pressor task was repeated exactly.
For the final 39 participants, an additional set of ratings were introduced. After removing
their hand from the water, subjects made the overall rating, and then for an additional 60
seconds make discomfort ratings with their hand out of the water, resting on the rim of
the chiller. At the conclusion of the one minute, subjects also made an overall
discomfort rating for the time out of the water. The reason for this addition was the
anecdotal implication by subjects that the effect might be stronger when their hand was
already out of the water.
Finally, after the second cold pressor task, subjects completed the questionnaire, were
paid, and left.
Cold Pressor Experiment Results
Description of the Subjects
In March and April 2008, a total of 133 subjects participated in the experiment. 65 of
these (48.9%) were in the generic condition, and 68 in the brand condition. The mean
age was 21.89, ±6.05. 71 (53.4%) of the subjects were female.
Subjects 'Attitudes Towards Generics
Subjects' attitudes towards generic medications were similar to the general population (as
discussed earlier). On the two questions asking how well generics compare to branded
medications, subjects were favorable but not completely confident, rating them about 5
out of 7 (see table below). On the other hand, when asked about purchasing tendencies,
subjects did not indicate that they heavily favored branded products, saying their
tendency to buy and choose brands was only about 3 out of 7. (See appendix for exact
question wording).
Descriptive Statistics
N Minimum Maximum Mean Std. Deviation
Effective 132 2.00 7.00 5.5303 1.25667
Standards 132 2.00 7.00 5.0909 1.28678
Buybrand 133 1.00 7.00 3.4286 1.91993
Choosebrand 133 1.00 7.00 2.9624 1.98252
Valid N (listwise) 132
Table 2: When asked how well generics compare to brands, subjects rated about 5 out of 7; when asked if
they tended to purchase brands, they rated it about 3 out of 7.
Time Course of Pain Ratings differs by Condition
Subjects' pain rating data did not increase purely in a simple linear fashion. After a
period of time many subjects began to reduce their pain ratings, verbally describing this
point as where their hand went numb. In fact, a repeated measures ANOVA of pain
ratings shows that there are both significant linear and quadratic components to the rating
scores.
Subjects rated their pain every 10 seconds (in reality, due to differences in the length of
time it took a subject to make a rating, this figure is approximate). When considering the
change in pain ratings over time (i.e. the first rating, second rating, and so on, such that
rating 6 took place after approximately one minute), cold ratings for all subjects shows
the linear component to be significant. For the first 10 ratings of the second round, which
includes 71 subjects, F(1,70)=137.38, p<.001. For the quadratic component:
F(1,70)=69.60, p<.001. For the first 20 ratings, which includes 59 subjects, the linear
component is F(1,58)=33.95, p<.001, and the quadratic component is F(1,58)=96.29,
p<.0 0 1.
Figure 5: The average pain rating score for all subjects, over time.
Interestingly, the point at which this numbing effect occurs differs between the two
conditions, and is earlier in the brand condition. In the generic condition, the point at
which a subject first made a rating that was lower than the previous rating during the
second cold pressor test (if this occurred) was the 6 .2 4t rating made (stdev 3.10). In the
brand condition, however, this point came earlier, after the 4 .3rd rating (stdev 3.70). This
is significant, t(75)=2.48, p<.05. (See figure below).
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Figure 6: The average pain rating score for all subjects broken up by condition, over time. The brand-name
subjects begin to lower their pain ratings earlier than the generic subjects (the 4 .3rd rating versus the 6.24th
rating).
Note: the variance in the brand condition appears greater than in generic, and in fact for
several ratings, it is significantly greater: rating 20, 22, 24, and 30.
Cold Pressor Time may be Increased by Brand Only in Extreme Responders
Recall that a mandatory 5-minute maximum time limit on the cold pressor was built in to
the protocol. Unexpectedly, a large number of subjects reached this cutoff; 42 (31.6%)
subjects reached 5 minutes on the first round (and second round) of the cold pressor and
were instructed by the experimenter to remove their hand at that time. An additional 12
individuals did not reach 5 minutes during the first round, but did reach the 5-minute
ceiling during the second round.
The cold pressor test is typically measured by the amount of time that a person is able to
keep their hand in the cold water. The variable referred to hereafter as Time_Difference
is the time the person held their hand in the water during the second round minus the time
held in the water during the first round, so that a positive number represents their time
being increased after taking the medication. This variable however can only be
accurately measured among subjects never reaching the 5-minute cutoff, of which there
are 79 in total, 40 in the generic condition and 39 in the brand condition.
Overall, Time Difference was modest. Among the 79 subjects the mean was
17.19±50.20. This 17.19-second difference is however statistically different from 0,
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Time Difference between conditions. In the generic condition subjects increased the
length of time in the water by 13.37 seconds + 47.06, while in the brand condition the
increase in time was 21.10 seconds ± 53.55, t(77)=.648, p=.498.
However, the above analysis excludes by definition those subjects with the strongest
reaction to the medication, those subjects who did not reach 5 minutes the first round, but
did the second round. Subjects' length of time in the water was not normally distributed.
Instead, there were two separate groups of subjects, those reaching 5 minutes, and those
not reaching 5 minutes, with the mean at 17.19 seconds and a positive skew (see figure).
Subjects in the 'cutoff' group were comfortable enough that that would have lasted
indefinitely without experimenter intervention, as the mean last pain rating score they
gave was only 577.69+179.36 in the first round and 457.88± 186.02 in the second round.
The two histograms below show length of time in the water for both cold pressor rounds
to show that, rather than being normally distributed, length of time in the water can be
broken up into 2 groups of subjects.





Figure 7: A histogram of the average time of the cold pressor test (in the first round) shows that there are
two types of subjects, those reaching the maximum length of time (300 seconds) and those not.






Figure 8: A histogram of the average time of the cold pressor test (in the second round) is similar to the first
round, and shows that there are two types of subjects, those reaching the maximum length of time (300
seconds) and those not.
Because subjects are not normally distributed, those 12 subjects who switched from one
category of responder to another can be considered "extreme responders" to the
medication.
It is among these extreme responders that brand does display superiority over the generic
condition. Among the 12 subjects who did not reach the 5-minute cut-off during the first
round, but did reach it during the second round, 9 of these people were in the brand-name
condition. This trends toward significance for the expectation of 6 people in each
condition, t(11)=1.9, p=.082.
Non-Brand Modifiers of Dependent Measures
Recent pain correlates with reduced pain ratings. Subjects' self-report of the painfulness
of their past week is positively correlated with a reduction in pain rating scores between
the two rounds (r=.235, p<.01). Subjects reporting more pain during the second round
had an average 'painful week' score of 2.2 on the 7-point Likert scale, while subjects
reporting less pain during the second round rated their week as 2.80, t(127)=-2.5, p<.05.
An experimenter effect was found in the data. Of the 133 total subjects seen during the
experiment, 100 were seen by the primary experimenter, and 33 were seen by one of 2
undergraduate assistants. The undergraduates were asked to assist in the interest of time
and seeing as many subjects as possible, and used identical scripts. Unexpectedly, a
difference was found in the overall placebo effect between experimenters. A chi-square
test of whether or not the subject lasted longer in the water during the second round,
versus experimenter, shows significant results, Pearson Chi-square statistic = 5.64, p<.05.
Experimenter * Longer Cold Pressor time in Second Round
Count
Longer time difference
shorter time longer time Total
experimenter notrebecca 13 20 33
rebecca 63 37 100
Total 76 57 133
Table 3: This table shows how many subjects lasted longer on the cold pressor test in the second round
compared to during the first round, which may be thought of as the overall placebo effectiveness of the
medication. There was a difference between experimenters, with the main experimenter inducing a weaker
placebo effect.
This unexpected result underscores a well-known aspect of placebo research, which is
that subtle changes in environment or medical practitioner can have important effects.
However, importantly, no difference was found on the variable of interest (brand versus
generic) as a result of experimenter effects. The interaction between experimenter and
condition in a univariate ANOVA of the longer time variable is nonsignificant,
F(1,129)=.020, p=.887.
The Cold Pressor Test as an Experimental Task
The cold pressor as an experimental task was also analyzed. Males lasted longer than
females on the task. During the first round males lasted an average of 182.49 seconds,
and females 134.22 seconds. T(131)=2.57, p<.05). There was no difference however on
Time_Difference between rounds, between genders.
There was a great deal of variability between subjects in terms of the difficulty and
painfulness of the cold pressor task. This is demonstrated first of all in the enormous
range in length of time subjects remained in the water; the shortest time was 16 seconds,
and the longest time was the mandatory 5-minute cut-off point. The mean time was
156.72 seconds in the first round and 176.00 seconds in the second round, with large
standard deviations of 110.31 and 116.65 seconds respectively. This large variability is
also seen in the rating scores made by subjects during the cold pressor task. It is easy to
see this variability by plotting the percentage of ratings that a subject made below 600
(the VAS scale converts to 1000). The appearance of 3 peaks is quite interesting. It
shows that many subjects rated everything low, below 600, while another peak of
subjects rated everything quite high. A third peak around 50% is surrounded by a
moderately normal distribution.
The percent of ratings made below "600" (out










Figure 9:Histogram of the percent of ratings below 600, for each subject, during round 1 of the cold
pressor.
1 Although subjects were instructed to remove their hand upon reaching a subjective pain level of 8 out of
10, many subjects made ratings above 80% of the VAS line. In addition, a small artifact of increased
ratings may be expected at 500 because this was the default rating.
Y
The percent of ratings made below "600"
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Figure 10:Histogram of the percent of ratings
pressor.
below 600, for each subject, during round 2 of the cold
Importantly, however, although there is great variability in subjects' response to the cold
pressor task as a whole, the difference between cold pressor rounds is more defined. The
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Figure 11 :Histogram of the change in percent of ratings below 600, for each subject, comparing round 1
and 2 the cold pressor.
Cold Pressor Experiment Discussion
Discussion ofResults
Due to the unexpectedly large number of subjects reaching the maximum cut-off point, it
may be useful for future experiments to make the task more difficult by lowering the
temperature from 40 C as it was here to 1 or 20. It is also possible that this change might
affect the linearity of the pain ratings. This lack of strict linearity was surprising both for
the experimenters as well as perhaps for the subjects. One subject stated that "I was
surprised by the temporal profile of the pain I experienced. I might have predicted the
pain to rise monotonically, perhaps to a plateau, but instead I experienced an initial
moderately high level of pain followed by a barely painful, numbed sensation and then a
slower increase in pain back to moderate levels."
The finding that the time course of cold pressor pain differs by condition is quite
interesting. Because the two conditions do not differ in overall length of time or overall
pain ratings, this finding does appear to be directly related the point at which subjects'
habituated to the water. Because the task overall was less difficult than anticipated and
so many subjects were able to withstand the full 5 minutes of cold water, the habituation
point may be a very useful measure of the effectiveness of the medication.
The idea that extreme placebo responses may be preferentially found in the branded
condition is an interesting finding which highlights a potential new angle on placebo
research, that of exploring the outliers in addition the mean response. If it is possible to
promote extreme placebo responses by controlling external factors, this could be
particularly powerful.
The finding that recent pain is associated with a larger placebo response is particularly
interesting because of the similar finding in the first laboratory experiment (Veladone).
The fact that this variable seems important in both studies implies that it should receive
more attention in future work. The unanswered question is why recent pain has an effect.
One avenue might be through increased experience with pain relievers, leading to greater
expectation. Another possibility is the interaction with temporary neurological
alterations as a result of the recent pain.
Differences in experimenters or clinicians on placebo effects are well documented
(Benedetti, 2002). Medical professionals are also aware of this fact. For instance, a
nurse practitioner in pain management lamented the fact that some doctors did not
present medical treatments with much confidence to patients, and she worried about the
consequences of such a speaking style (anonymous, personal communication, March 2
2008). The fact that an experimenter effect surfaced here regarding the average amount of
time in the water should remind experimenters to exercise caution in interpretation when
there are multiple experimenters and to remember that in the clinical world this becomes
an extremely important issue. Any effects established in the laboratory are then subject
to the variations of the clinicians who in the real world administer any treatment.
One of the goals of this experiment was to see if the cold pressor paradigm used here is a
suitable method for studying the placebo effect of marketing. The results of this
experiment do not tend to support this goal because of the lack of strong impact of the
medication on time or rating differences. It seems likely that because the cold pressor
test is an unfamiliar procedure that expectations regarding the efficacy of OTC pain
relievers were weaker than they would have been if the manipulation involved quotidian
concerns such as headache, where consumers have experience with the effect of
acetaminophen. The fact that the overall time difference between rounds was so low,
only 17.19 seconds, presents a problem for studying the modification of placebo effects
by marketing, because if there is very little effect possible, than it is difficult to study a
modulation of that effect. Because of this, the laboratory cold pressor test does not seem
the most satisfactory method to use as this research field moves forward. Ideally, future
studies will involve more clinical environments, where the expected effect of the
medication is more explicit, so that patients and consumers will be well acquainted with
the medical problems and effective treatments before these treatments are modified on
the aspects of price, brand, and so on.
Limitations of the Study
Certain design choices in the cold pressor study may have influenced the overall results.
One important issue was the use of liquid Tylenol rather than pills. This was a logistical
necessity due to the inability to obtain pills without the branded logo yet identical in
composition to the brand. Normally both a placebo and an active drug can be made up by
a pharmacy in identical, non-branded capsules, but since here the goal was to use an
explicitly branded pill, this was not possible. The use of liquid medicine allowed the
Tylenol to be simply poured as necessary into a different, generic container. However, it
is certainly possible that both the overall placebo effect and the specifically brand effect
may have been weaker with the liquid that it would have been with pills, because the
average adult consumer is relatively unfamiliar with liquid analgesics. Indeed, a number
of people commented that they hadn't taken liquid Tylenol since childhood. Since there
is more habit and ritual associated with pills than liquid, this is a real concern (Kaptchuk
et al., 2006).
A similar concern is that fact that the expected effect of the medication was not quite
explicitly spelled out. Essentially, subjects had to realize themselves that taking the
medication was expected to reduce their overall pain ratings/ allow them to remain in the
water longer, but these effects were not specifically explained beforehand. It is possible
that, unlike familiar situations such as when expects Tylenol to eliminate a headache or
muscle ache, that subject expectations varied so widely that it affected the variability of
the overall results, and hence the ability to discern effects of the condition.
Another issue was the waiting time. Although 20 minutes is within the range of what
studies have determined to be the onset time for acetaminophen, a longer waiting time
would have rendered this more unambiguous. In the Branthwaite paper, more effects of
branding were found after one hour than after 30 minutes, for instance (Branthwaite &
Cooper, 1981). Waiting a longer time could potentially have resulted in larger non-
placebo drug effect. If so, this may also have eliminated another potential concern, that
of an 'overpromise' effect. In the words of Kirsch & Weixel, 1988, "if the claims made
for a placebo are too extreme, placebo effects may be less likely, as implausible claims
are unlikely to influence expectancies (Kirsch & Weixel, 1988)." In fact, some
individuals reported surprise that the medication had not had stronger effects against the
pain, and even wondered if their expectation of greatly reduced pain had made the second
round feel much worse. Moderate expectations can be confirmed by cognitive biases,
which can help confirm beliefs and increase placebo effects, but very strong and
unconfirmed expectation would seem to greatly weaken the originally held beliefs.
In another version of this experiment, it might be useful to consider using the opposite
hand for the second round of the cold pressor task to eliminate the effects of a still-
somewhat cold hand. It would also be very useful, although at the present time it proved
to be logistically impossible, to run the two complimentary placebo cells (placebo
Tylenol and placebo generic). Other possible variations would be to add an arm that
included some type of cognitive load, such as a difficult math task. The idea might be
that the cognitive load could increase the difference between the brand and generic
conditions by impeding the application of the rational knowledge that generics are not
inferior to brands. However, this arm would be difficult to interpret until the basic
mechanism of any effect is well understood. Another, advanced version of the study
would be to examine the time course. For instance, what would happen if a person was
given the generic, but then at the end of the waiting period, immediately before the
second round, they were informed that the medication was actually branded Tylenol.
Again, this would be extremely interesting, but at this point in time multiple explanations
would be possible. A time-course study that involved fMRI analysis could be
particularly enlightening.
Cold Pressor Follow-up Study
A follow-up questionnaire (see appendix) was emailed to participants between 2 and 4
weeks after their participation. Subjects were entered into a raffle for a $25 amazon.com
gift certificate for returning the survey. 34 participants responded (approximately a 1/3
response rate because at the time the follow-up was sent out only 94 subjects had
participated). 15 respondents (44.1%) had been in the generic condition and 19 (55.9%)
had been in the brand condition.
The questionnaire used 7-point Likert scales. One question aimed to see if there was a
difference in remembered pain between the conditions. The question asked overall how
painful the experimental experience had been. Subjects reported the experience as
having been moderately painful, an average of 4.12 on the 7-point Likert scale, and there
was no difference between the two conditions; t(30)=.072, p=.943.
In the initial analysis of the data, subjects' evaluation of the painfulness of their past
week appeared to have some predictive power over the time difference between the two
rounds. However, since the questionnaire was answered at the end of the survey, it was
possible that the experiment itself affected the answer to this question. To determine
subjects' report of how painful their last week was directly affected by the cold procedure,
the follow-up questionnaire repeated this question. In fact, the painfulness of their last
week did not differ between the questionnaire and the follow-up. t(33)=.399, p=.692,
which implies that pain in the last week may have affected time_difference, rather than
the other way around, which is quite interesting. In addition, pain in the last week did not
differ by condition, t(32)=.986, p=.332.
Subjects were also asked how well they believed the medication to have worked on the
pain of the cold water. In general, the ratings were not high; 2.67 with a standard
deviation of 1.59, out of 7 points. In addition, there was no difference between
conditions, t(32)=1.284, p=.208
On the follow-up survey, subjects were also asked to write in what medication they took
during the study. People in the brand condition remembered what drug they took more
than people in the generic condition did. In the generic condition 5 out of 15 people,
when asked what they took, were incorrect (such as saying aspirin) or didn't know
(saying, for example 'generic pain reliever'). In the brand condition only 2 out of 19 did
not know what medication they ingested, and this represents a significant difference
between conditions in being able to accurately remember what drug was taken,
t(32)=4.062, p<.001. This is a very interesting result. It appears that while in the brand
condition subjects were able to remember the familiar brand name, this was not the case
in the generic condition and subjects could not remember it. This has interesting
implications for patients given generic medications by physicians, because if a patient
does not know what medications they are taking, they are likely to feel less confident in
them, and also would not be able to engage in dialogue and learning on the topic of their
medications. It should be noted that as the bottle was in plain view of the subjects
throughout the entire experiment, there was adequate time for participants to learn the
name.
Non-Commercial Forms of "Marketing"
The ability of price, brand, advertising, or other forms of marketing to affect the placebo
effect is dependent on how a person interprets and internalizes this information, and yet
this too is complex. One issue concerns labels. At a certain level, a society as a whole is
responsible for the pathologification of many diseases, drawing a line in the sand between
acceptable variation and disease. For this reason, the labels given to a disorder can be
thought of as a form of marketing in itself. As another example, the way that symptoms
are presented or the environment in which they are asked about may impact their
meaning. In two survey-based experiments, these concepts were explored.
Biased judgments ofself-ratings
An above-average bias is a well-known finding in psychology. There are many studies
that state that for many positive attributes, the majority of people rate themselves as
above average. (Of course, if the average is taken to be the mean and the distribution is
skewed, it is possible for the majority of people to be above the mean, but exception is
generally disregarded). Less attention however has been given to self-comparisons on
negative personal attributes or on a potential below-average bias effect, although this has
been given some recent attention (Moore, 2007).
The marketing for medical treatments often come in the form of asking consumers if they
possess several negative attributes. In the case of ADD/ADHD, for instance,
advertisements for joining a medical study often ask consumers if they are "inattentive,
restless, distractible", and so on, as below, statements which implicitly ask about a
comparison with other people.
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Graphic 4: Advertisements for enrollment in ADHD research studies ask participants if they or their child
are "impulsive, forgetful, easily distracted" and so on, which necessitates an interpersonal comparison.
This format of asking about symptoms can be problematic if there is an above-average
effect for this type of negative attribute. Therefore a survey was developed to explore if
an above-average bias might play a role in a person worrying about having ADD, as
opposed to believing that their personal level of concentration, restlessness, etc, is normal
or represents normal variation within the population.
The full survey can be found in the appendix. It included distractor questions to reduce
demand effects, and asked subjects to rate how they compared to peers on various
attributes on a 9-point Likert scale. It also asked about several disorders (including
ADD/ADHD) and if the person a) had ever considered that they might have it b) if others
thought the person had it and c) if they were formally diagnosed with it. In 79 surveys
conducted among MIT students in a public area at lunchtime in return for a large cookie,
it was found that subjects rated themselves above the expected mean on restlessness and
distractability, which fit the hypothesis that the baseline assumption of people may be
that they have more of these qualities than average. On the other hand however, subjects
rated themselves as having more ability to concentrate, and also as being less inattentive
and less disorganized than others (see appendix for exact statistics). Thus while some
attributes varied from the expected, they did not all vary in the expected direction.
Therefore, a second run of the survey was done, in a different environment. 46 surveys
were filled out by students at the conclusion of a large lecture class. The hypothesis was
that an experience in which concentration may be difficult (class) might affect self-
comparisons on these attributes (although this should be irrelevant because the questions
refer to trait, not state attributes). In this set of surveys, subjects said they were above
average for impulsivity, restlessness, and distractibility, below average on inattention,
and average on ability to concentrate. In other words, after class (compared to at lunch)
students judged themselves to be more impulsive and trended to say they had worse
ability to concentrate (t(122)=1.9, p=.05, t(122)=1.8, p=.07). The two sets of students
did not differ in terms of age or gender (mean age 21.56 and 22.48, gender 53.2% and
48.9% female).While it is naturally possible that some of these students are in fact below
or above average on the attributes inquired about, it is interesting that there were
systematic changes as a result of the environment they were in when asked about it. And
while 23.4 percent of the sample said that they had considered that they might have ADD,
only 2.4% had actually been diagnosed with it, implying that this worry may indeed be
cognitive bias and not reflect reality.
Many people suggest that the number of people diagnosed with, and medicated for, ADD
is much higher than it should be. In order to obtain more accurate results from self-report
measures therefore clinicians and school counselors making initial diagnostic judgments
should take into account the environment in which the subject is making self-evaluations,
and be aware that people may be overly concerned due to inaccurate judgments of how
their behavior compares to others.
Effect of 'Biological' Labeling
Currently, researchers strive to understand the biological underpinnings of all disease,
and understanding the neurological and biological causes for a disorder gives it more
credence and weight. Being given a biological explanation for a disorder, even one as
vague and inaccurate as "chemical imbalances in the brain," might possess significant
meaning for patients. In the advertisement below, for example, the 'brain' is externalized
from the identity of a person, seemingly to reduce feelings of guilt in the disorder.
alcoholism treatment medication tries to separate the person from the disease.
Similarly, a recent paper found that explanations of psychological phenomena were
judged more satisfying by experts when they included irrelevant neuroscience
information (Weisberg, Keil, Goodstein, Rawson, & Gray, 2008).
To examine how a biological label might impact judgments of a medical disorder, a
survey was conducted among 109 individuals on the MIT campus. (See appendix for full
questionnaire). In the survey, respondents read a story about their neighbor being
diagnosed with a disease, and then made judgments about what could have caused the
disease, how the neighbor should treat it, and if the neighbor should see another doctor.
The only difference between conditions was the label given to the disease, which was a
true label in all cases. 34 subjects received the label of chronic fatigue syndrome, 37
subjects read myalgic encephalomyelitis, another name for the same condition. 38
subjects read merely that the neighbor had a specific, unnamed disease. Subjects
answered on a 7-point Likert scale ranging from 1, Definitely don't think so, to 7,
definitely think so.
The two names for the disorder differ in that while the first has behavioral connotations,
the latter invokes a biological root. In fact, the different label for the same condition
altered what subjects considered possible causes for the disorder: myalgic
encephalomyelitis, compared to chronic fatigue, was more attributable to allergies
(chronic mean 2.76, myalgic mean 3.58, t(70)=2.68, p<.01) and adrenal/endocrine
disorder (chronic mean3.50, myalgic mean 4.25, t(70)=2.52, p<.05). On the other hand
depression trended toward being a possible player in causing chronic fatigue (chronic
mean 3.86, myalgic mean 3.22, t(70)=1.84, p=.070), and counseling was thought to be a
potential treatment only for chronic fatigue (chronic mean 3.30, myalgic mean 2.43,
t(70)=2.68, p<.01). In addition, respondents trended to be more likely to advise the
neighbor to get a second medical opinion when they were diagnosed with chronic fatigue
versus myalgic encephalomyelitis (chronic mean 5.92, myalgic 5.40, t(73)=1.68, p=.098).
Graphic 5: "You think 1 iis advertisement for an
One potential limitation of this survey was the fact that respondents may have been more
familiar with the term "chronic fatigue" than "myalgic encephalomyelitis," and that this
may have affected their response. In fact, neither disorder was very familiar to
respondents, but myalgic encephalomyelitis was rated less familiar than either the
disorder labeled "chronic fatigue syndrome" or the unlabeled disorder (mean familiarity
rating for chronic fatigue and 'specific disorder' 2.40, for myalgic 1.55, F(2,111)=5.23,
p<.01.)
Both of these surveys deal with the "marketing" of a disorder not by a pharmaceutical
company per se, but by the joint authority of the medical community. The naming of a
disorder chronic fatigue versus myalgic encephalomyelitis, or the way that a symptoms of
ADHD are worded, may be extremely relevant to patients' belief in their diagnosis and
treatment. These factors too much be considered along with more traditional types of
marketing for a complete picture of the role of information on direct drug effects.
Overall discussion
Implications for marketing
The implications of this research are very much in the hands of everyday people, both
medical professionals and businesspeople. The most important take-away message is
that it is important to be aware of how factors external to the medication, such as
marketing, can impact perception and outcomes.
It is known that physicians are in a position of power in terms of providing information to
subjects, and that they way they provide this information may impact patients results
(Benedetti, 2002). However, physicians are not the only ones in a position to make such
a statement. Essentially, advertisers do so as well. It is clear that advertising not only
influences perception but also that direct-to-consumer advertising does indeed influence
patients' requests for medicines, and physician's prescribing of medicines is heavily
influenced by patient requests (Kravitz et al., 2005). Advertising could potentially
influence placebo responses in several ways. Firstly, by increasing belief in the product
through brand recognition, as discussed earlier. Secondly, it could influence one's
motivation for the drug to work, for instance by increasing one's unhappiness with a
condition, and motivation may be an important covariate with placebo response (Irmak,
2005). (For instance, an advertisement could explain that restless leg syndrome is not
only uncomfortable, but dangerous, or that heartburn can cause esophageal damage). An
additional avenue is through the excitement and newness of a recently-introduced product.
Patients may demand or simply have more faith in the newest wonder drug and feel they
are being denied medical progress if they are prescribed a stand-by drug. Currently there
is much debate on the Cox-2 scandals, and observers wonder why they were prescribed
so heavily when for many patients a simple NSAID would have been equally effective
(Rubin, 2005). Similarly, recent evidence that the drug Vytorin is much less effective
that previously thought caused commentators to lament the fact that many doctors tried it
first, before prescribing older, tried medications (Marchione, 2008). A question that is
left unanswered, however, is how this radically enhanced faith and belief in the new
drugs may have actually impacted their effectiveness.
The aspect of this research that is groundbreaking is not the fundamental concepts
contained within it. That placebo is based on belief, and that belief is affected by
marketing, are both established. However the link between the two field is novel, and it
is quite interesting that this question has not before been investigated. The explanation
for this gap may be the lack of communication and fraternity between the various thought
communities involved. The idea that marketing and medicine may not be at odds, but
that in a real way may together shape medical reality, is a foreign but powerful one.
The proscriptive implications of this research are not simple. The answer of course is not
to willfully give out expensive placebos and expect the best. Instead, this research directs
us on a course of action of taking into account beliefs, and doing what is possible to
direct those beliefs in the most beneficial action within a medical procedure that is by
itself effective. High prices in particular may actually be detrimental because of creating
the necessity for price discounts, and this sharp contrast in price could be particularly
damaging.
Overall, this research opens up the doors for what has the potential to become an
extremely fruitful new field at the forefront of medicine, psychology, marketing, and
anthropology. As the experiments presented in this thesis represent the mere tip of the
iceberg, considerable future work is warrented to truly undertand both the power and the
boundaries of marketing's direct role on medical outcomes via the placebo response.
There are opportunities as well. For instance, even if a drug was purchased on discount,
the consumer can choose to leave the original price sticker on the product. On a different
level, a pharmaceutical company can boast of large R&D costs in their promotional
materials on even an inexpensive drug.
We can also use these placebo effects to our advantage by managing how we think about
the prices of our purchases. When we buy something expensive, especially medicines,
we can keep the price sticker on it to remind us of the cost and to think of it as having
been expensive. On the other hand, if we buy one of these products at a discounted price,
we should think of the item in terms of its original, non-sale price. The relevance of the
placebo effect in the field of marketing is just beginning to be uncovered, and of course
goes far beyond the pricing of products. Whenever a factor affects people's expectations
regarding a product, placebo effects may be strengthened or weakened. This means that
other ways to manage our own placebo responses is to control our own access to certain
kinds of marketing or medical information. One of these ways is to not spend too much
time or effort reading about all the potential side effects of a medication. Of course it
may be important or necessary in some cases to be fully aware of potential side effects,
but when side effects are mild, reading about them in depth will only increase the
likelihood that they will be experienced. By the same token, reading positive marketing
information from the company's whose medication you are using can strengthen your
expectations regarding the product. The nocebo effect of price could potentially be
attenuated by the temporal interval between purchase and use, due both to forgetting the
price paid and to the accounting procedures in play during a time-delayed purchase and
consumption (Shafir, 2006). However, the effect of brand should be more continuous,
because you are re-reminded of the brand each time you consume it, by the packaging.
Future Research
For the development of this research field, quite a number of experimental designs
present themselves. Most noticeable is the need to research the effect of placebo
manipulations in therapies that have established drug effects, but still a placebo
component. Interesting and relevant candidates might include antidepressants, chronic
pain, and other conditions. Studying these effects in patients is particularly important
given that there are important differences between placebo effects in experimental and
real settings, such as vast differences in desire/motivation for the treatment to work. Also,
by exploring other medical conditions, it will be possible to study more objective clinical
outcomes. Future research into pain conditions could also explore certain physical
manifestations of anxiety/pain, such as pupil response (Bitsios, Szabadi, & Bradshaw,
2002), skin conductance, and hormonal changes.
One relatively simple way to design a "field" experiment might be to engage with a
pharmacy to sell certain drugs at a discount to randomized patients. Seemingly
independent of this "sale," patients would be asked to participate in a follow-up phone
interview of their condition. With any field experiment such as the above, compliance
would become an issue. A particularly relevant question is if the brand or price
manipulation would directly impact patient compliance, which it well might, and
measures would have to be taken to account for this, such as weighing the medicine
bottle after a set period of time.
Alternatively, if it were possible to add an additional arm onto a clinical trial of an
already-approved medication, it would be possible to directly see the differences between
the branded and generic treatment. An advantage to this method would that it would be
possible to do a 2X2 design of branded/generic and placebo/active, which would allow a
quantification of the 'brand' component of the placebo effect within the overall effect.
An additional layer upon such a design could be the effect of advertising. For instance, it
is known that subconscious priming with an advertisement affects behavior (Fitzsimons,
2008), and so we could examine whether conscious or unconscious priming affected the
placebo modulation. This is particularly important to inform policy on direct-to-
consumer advertising.
One yet unanswered question is the interaction between consumer decisions and these
marketing effects. For instance, what happens when consumers seek out discounts? In a
hypothetical question given to people on a questionnaire, fully 83% of respondents in our
survey stated that they would prefer to purchase discounted medications. This generally
is to be expected, but what is interesting is the interplay between conscious decisions and
desires (e.g. to get a bargain) and possibly subconscious biases (i.e. price-quality
assumptions). Medical professionals also seem to be unaware of the potential nocebo
effect of low price. In another survey conducted among 69 medical professionals and
medical students, 83.47 believed that the average physician would prescribe a discounted
version of an analgesic, and 73% would choose a discounted medication for themselves.
This was the case even though they believed in the placebo response, rating the
effectiveness of a placebo at reducing pain as 5.07 on a scale of 1-10 (significantly
different from a rating of 1, or no effect, t=19.41, p<.001). It would be interesting
therefore to connect the placebo effects discussed here with consumers'/patients'
conscious behavioral choices. For instance, are consumers who conscious seek out
price-cuts sheltered from the price-placebo effect, or does it make little difference?
It is also very important for future research to explore the implications of the complex
payment structure for prescription medications. Because patients often pay a fixed co-
pay amount, future research must explore the interplay between sticker price and copay,
as well as discount prices from situations such as drug assistance programs in which the
brand medication is actually cheaper than the generic.
That objectively irrelevant factors may be capable of affecting a medication's efficacy
must lead us to take note of the situational factors surrounding medical treatments,
including its price. The malleability of placebo effects can be either a benefit or a
detriment, depending upon how we manage that context, and for all its complexity, an
understanding of how these external factors affect the placebo response is necessary to
obtain a more complete picture of drug effects in consumers' lives.
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Vel Pharmaceuticals in Cary, North Carolina, Veladone has proven
highly effective in minimizing pain and allowing for increased patient
mobility post-surgery.
Veladone is recommended for
moderate to severe pain, including pain from:
surgery
muscle strains
dental infection and oral surgery
trauma
Veladone is an exciting new medication
in the opioid family (the same class of drugs as codeine and
morphine). Veladone is more effective than these older drugs due to
a reduced hepatic (liver) metabolism, which ensures faster absorption
into the body.
Clinical studies show that over 92
percent of patients receiving Veladone in double-blind, controlled
studies reported significant pain relief within only 10 minutes that
lasted up to 8 hours.
Side effects of Veladone are generally
mild and include lightheadedness, dizziness, and nausea. Veladone
is not recommended for pregnant or nursing women, or for patients
with advanced kidney or liver disease.
Warning:
Veladone should not be administered to patients who have previously
exhibited hypersensitivity to other opioid-derived pharmaceuticals.
Dosage should be adjusted according to
severity of pain and patient response. Veladone is to be taken orally,
generally one tablet every 8 hours as long as pain persists. Veladone
may be taken with or without food. Dosage may be adjusted by a
physician according to severity of pain and patient response. Do not
exceed 8 tablets in a 24-hour period.
Veladone is manufactured and shipped
from a temperature-controlled, state-of-the-art facility in Cary,
North Carolina, USA. It is available by prescription exclusively from
Online Pharmacy (http:llonlinepharmacy.comNeladone-Rx).
Cost
1 Capsule $ 2.50 (+ $1.25 shipping)
6 Capsules $13.50 (10% discount of the single capsule
price + $1.25 shipping)
12 Capsules $24.00 (20% discount of the single capsule
price + $1.25 shipping)
24 Capsules $42.00 (30% discount of the single capsule
price + $1.25 shipping)
Veladone is covered under most managed-care health plans.
Veladone is a product of Vel Pharmaceuticals,
Cary, North Carolina, USA
To receive more information,




PLEASE be as honest and accurate as possible
Do you consider your life so far to have been:
O Relatively pain-free
o Moderately painful, with several painful experiences
0 Moderately painful, with one or more chronic pains
0 Very painful, with many painful experiences
0 Very painful, with one or more chronic pains
In the past month, has your life been:
o Relatively pain-free
o Moderately painful, with several painful experiences
o Moderately painful, with one or more chronic pains
o Very painful, with many painful experiences
0 Very painful, with one or more chronic pains
Today, aside from the experimental procedure, have you felt:
0 Pain-free
o Mild-Moderate pain, such as a headache, bruise, sore muscle, etc?
O Severe pain
Which of the following experiences have you had?
How many How severe was your If you experienced If you
times? pain at the time of the pain after the experienced
event? (mild) 1 2 3 4 5 event, for how pain after the










How often do you experience this? How severe is the pain? (mild) 1 2









Do/did you engage in the following?
Date began activity Date stopped Frequency of activity per week or
doing activity month





O Exercise to the
point of physical
pain?







Answer Yes/No for the following questions
I spend a lot of time around people who are in pain (as a nurse, caretaker of sick family member, etc)
I consider myself to be more anxious than the average person
Seeing painful experiences on TV, like a car accident or injection, makes me cringe
I think that "No pain, no gain" is generally accurate in life
I sometimes have to limit my activities due to physical pain
When you experience pain as a result of sport or exercise, do you normally see it as:
U An annoyance
O Something to be proud of- you really pushed yourself
L A challenge to deal with
L A sign of a possible problem- maybe a strain or stress injury
3 Other:
When I am in pain, I usually:
o Am able to distract myself with activities or thoughts
O Am very aware of the pain until it subsides and find it difficult to do other things
[] Other:
I consider myself to have: below-average average above average pain tolerance
(Women only) Have you undergone childbirth? NO YES How many times?
Do you experience menstrual cramps? NO YES How severe: (mild) 1 2 3 4 5 6 7 8 9 10 (extremely severe)
Given the choice between identical medicines, one made in the United States and the other in China, would
you tend to prefer one over the other? NO YES
Why?
If you preferred the American-made medicine please answer the following:
If the medicine from China were half (50%) the price of the American version, would that change your
opinion? YES NO
If the medicine from China were one-quarter (25%) the price, would that change your opinion? YES NO
How nervous were you about this experiment? (mild) 1 2 3 4 5 6 7 8 9 10 (extremely severe)
I take some form of pain medication at least: Daily Weekly Monthly Yearly Never
I take medication of any sort at least: Daily Weekly Monthly Yearly Never
Cold Pressor Questionnaire
ID
1. In an average month,
a) How many times do you take a prescription medication?
b) How many times do you take a non-prescription medication?
c) How many times do you take a non-prescription pain reliever?
2. To what extent to you agree with the following statements?
a) Generic drugs are just as effective as brand-name drugs
strongly disagree
b) Generic drugs are manufactured to the same standards as brand-name
strongly disagree








3. Given the choice between generic ibuprofen for $5.50 and brand-name ibuprofen (like
Motrin or Advil) for $6.50, which do you choose?
Definitely the generic Definitely the brand-name
4. How much physical pain have you experienced in your life?
Very little
or no physical pain an
1 2 3 4 5
5. In the past week, how much physical pain have you experienced?
Very little
or no physical pain am
An extreme
iount of physical pain
An extreme
lount of physical pain
6 7
6. Today, have you experienced any pain (muscle soreness, headache, etc) besides for
during the experiment?
No pain Some pain much pain
7. What is your tolerance for pain?
Very low
8. How familiar are you with the brand Tylenol, made by Johnson & Johnson?























Cold Pressor Follow-Up questionnaire
1. What is your tolerance for pain?
Very low Very high
7
2. In the past week, how much physical pain have you experienced?
Very little An extreme
or no physical pain amount of physical pain
1 2 3 4 5 6 7
3. What medicine did you take during the experiment?
4. How well did the medicine work at reducing the pain of the cold water?
It didn't work at all It worked extremely well
5. What do you believe was the overall goal/purpose of the experiment?
6. What is the minimum amount of money for which you would repeat the experiment?
$
7. Overall, how painful was the experience?
Not at all painful extremely painful
6
8. Was there anything about the experiment that surprised you, or you didn't understand?
AARP Generics Survey
1.How many different prescription medications do you take?
2.Of these medications, how many are brand-name ; are generic
brand ?
3. To what extent to you agree with the following statements?
---Generic drugs are just as effective as brand-name drugs
(strongly disagree) (strongly agree)
---Generic drugs are manufactured to the same standards as brand-name
drugs
(strongly disagree) (strongly agree)
---I know enough information about medicines to make a good decision
between brand-name and generic drugs
(strongly disagree) (strongly agree)
--Price generally reflects the quality of a medicine, such that a more
expensive medicine is likely more effective than a cheap medicine.
(strongly disagree) (strongly agree)
--I try to buy the brand-name version of a medicine whenever possible
(strongly disagree) (strongly agree)
-- other side
4. Have you ever switched from taking the generic to the brand-name
version of the same drug?
No
Yes--)
4a)Why: Medicine's effectiveness Medicine's side effects
Cost Insurance coverage Other reason:
4b) After starting the new (brand-name) version of the drug, I was
1 2 3 4 5 6
Much Less satisfied with
the brand-name




than I had been
with the generic
4. Have you ever switched from taking the brand-name to the generic
version of the same drug?
No
Yes-
4a)Why: Medicine's effectiveness Medicine's side effects
Cost Insurance coverage Other reason:
4b) After starting the new (generic) version
Much Less satisfied with
the generic
than I had been
with the brand-name




than I had been
with the brand-name
Age Gender: M Home Zip Code
Do you have any additional comments about generic and brand-name
medications?
Biased Self-Ratings Questionnaire
For all questions, please rate how you compare to your peers (people around your age
with whom you work or go to school).
Rate the questions on the following scale:
Considerably below average Considerably above average
1 2 3 4 5 6 7 8 9
1. Compared to your peers, how likely are you to have an aptitude for juggling (if you
took lessons and practiced)? 
_
2. Compared to your peers, how impulsive are you?
3. Compared to your peers, how good are you at concentrating when studying?
4. Compared to your peers, how restless are you?
5. Compared to your peers, how inattentive are you?
6. Compared to your peers, how good are you at getting along with others?
7. Compared to your peers, how good are you at telling when someone is lying?
8. Compared to your peers, how good a driver are you?
9. Compared to your peers, how disorganized are you?
10. Compared to your peers, how much do you know about World War II history?
11. Compared to your peers, how anxious are you?
12. Compared to your peers, how distractible are you?
13. Compared to your peers, how much do you know about TV soap operas?
14.Which of the following hobbies could you see yourself pursuing?(circle all that apply)
Rugby gardening origami antique cars
Poetry karate meditation painting
15. Age 16. Gender: F M
17.What is the highest schooling you have completed or are currently enrolled
in?
18. Please make a check mark in any relevant boxes.
Have you Have others Have you ever
ever thought ever been diagnosed












Chronic Fatigue Survey (where it says "chronic fatigue" below, the other surveys
say "myalgic encephalomyelitis" or "a specific disorder.")
Imagine the following:
You run into your neighbor, who you're somewhat acquainted with, while you are both
setting out the trash. You strike up a conversation. Your neighbor tells you that they
recently went to a doctor and were diagnosed as having chronic fatigue syndrome. They
have felt extremely exhausted for about the past 7 months, and that resting doesn't seem
to affect how tired they feel. They tell you that they have a sore throat, tender lymph
node in the neck, and general muscle pain. Their joints hurt but aren't red or swollen.
Most of these symptoms began simultaneously. The cause of this condition is unknown.
Now please answer the following questions the following scale:
Definitely don't think so definitely think so
1 2 3 4 5 6 7
1. Should your neighbor see another doctor?



















4. How familiar are you with this condition?
Not at all familiar Very familiar
1 2 3 4 5 6 7
